Information
-
Patent Application
-
20040142952
-
Publication Number
20040142952
-
Date Filed
February 18, 200420 years ago
-
Date Published
July 22, 200420 years ago
-
CPC
-
US Classifications
-
International Classifications
Abstract
The present invention provides triazoloquinazoline and pyrazolotriazolopyrimidine derivatives represented by the following general formula (1):
1
Description
TECHNICAL FIELD
[0001] The present invention relates to novel triazoloquinazoline and pyrazolotriazolopyrimidine derivatives which exhibit an affinity to an adenosine A3 receptor, a pharmaceutical composition containing the derivatives, an adenosine A3 receptor affinitive agent, an intraocular-pressure reducing agent, a pharmaceutical preparation for prevention and treatment of glaucoma, and an intraocular-pressure reducing method.
BACKGROUD ART
[0002] J. Heterocyclic Chem., 31, 1171 (1994) discloses that 2-aryl-8-fluorobenzyl-1,2,4-triazolo[5,1-i]purine is useful as an adenosine A2 receptor antagonist.
[0003] Eur. J. Med. Chem., 28, 569 (1993) describes that a pyrazolotriazolopyrimidine derivative exhibits an adenosine A2 receptor antagonist effect. Also J. Med. Chem., 34(1), 281 (1991) describes that a triazoloquinazoline derivative exhibits high affinity to a benzodiazepine receptor.
[0004] An object of the present invention is to provide a novel compound having an affinity to an adenosine A3 receptor.
DISCLOSURE OF THE INVENTION
[0005] To achieve the object described above, the present invention provides triazoloquinazoline and pyrazolotriazolopyrimidine derivatives represented by the following general formula (1):
2
[0006] wherein R1 represents a lower alkyl group, a phenyl group, a lower alkoxycarbonyl lower alkyl group, or a carboxy lower alkyl group; R2 represents a pyridyl group, a furyl group, a thienyl group, or a phenyl group which optionally has 1 to 3 groups selected from lower alkyl group, halogen atom, phenyl group, halogen-substituted lower alkyl group, hydroxy group, lower alkoxy group, N,N-di lower alkylamino group, lower alkylthio group, lower alkanoyloxy group and nitro group as a substituent; A represents a pyrazole ring which is optionally substituted with a group selected from lower alkyl group, phenyl lower alkyl group, lower alkoxycarbonyl lower alkyl group, carboxy lower alkyl group and hydroxy lower alkyl group as a substituent, or a benzene ring which is optionally substituted with 1 to 2 groups selected from halogen atom, lower alkyl group, nitro group and lower alkoxy group as a substituent; with the exception that A is a benzene ring, R2 is a pyridyl group or a phenyl group, and R1 is a methyl group, an ethyl group or a phenyl group.
[0007] These triazoloquinazoline and pyrazolotriazolopyrimidine derivatives of the present invention are novel compounds which have never been described in reference documents.
[0008] The pyrazolotriazolopyrimidine derivative in the present invention is represented by the following general formula (1-1):
3
[0009] wherein R1 and R2 are as defined above.
[0010] In the present invention, it is particularly preferable that R2 is a phenyl group which optionally have one group selected from lower alkyl group, halogen atom, halogen-substituted lower alkyl group and hydroxy group as a substituent, or phenyl group which has 1 to 3 lower alkoxy groups.
[0011] In that case, A is preferably a pyrazole ring, or a benzene ring which is optionally substituted with one halogen atom as a substituent. More preferably, R1 is an n-butyl group and R2 is a phenyl group which optionally has one group selected from lower alkoxy group, lower alkyl group, halogen atom and hydroxy group as a substituent.
[0012] Specifically, preferable compound is a compound selected from compound in which A is a pyrazole ring and R2 is a phenyl group having any one of lower alkoxy group, lower alkyl group or halogen atom as a substituent, compound in which A is a benzene ring and R2 is a phenyl group having one group selected from lower alkoxy group, halogen atom and hydroxy group as a substituent, and compound in which A is a benzene ring substituted with one halogen atom and R2 is a phenyl group, and the compound includes the following compounds:
[0013] 5-n-butyl-2-(4-chlorophenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine,
[0014] 5-n-butyl-2-(4-chlorophenyl)-1,2,4-triazolo[1,5-c]quinazoline,
[0015] 5-n-butyl-2-(4-ethoxyphenyl)-1,2,4-triazolo[1,5-c]quinazoline, and
[0016] 5-n-butyl-9-chloro-2-phenyl-1,2,4-triazolo[1,5-c]quinazoline.
[0017] The compound of the present invention is more preferably a compound wherein R2 is a phenyl group which has a lower alkyl group or a halogen atom at the 4-position, and the compound include the following compounds:
[0018] 5-n-butyl-2-(4-chlorophenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine,
[0019] 5-n-butyl-2-(4-fluorophenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine,
[0020] 5-n-butyl-2-(4-methylphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine,
[0021] 5-n-butyl-2-(4-chlorophenyl)-1,2,4-triazolo[1,5-c]quinazoline,
[0022] 5-n-butyl-2-(4-bromophenyl)-1,2,4-triazolo[1,5-c]quinazoline, and
[0023] 5-n-butyl-2-(4-chlorophenyl)-9-chloro-1,2,4-triazolo[1,5-c]quinazoline.
[0024] The compound of the present invention is still more preferably 5-n-butyl-2-(4-methylphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine or 5-n-butyl-2-(4-bromophenyl)-1,2,4-triazolo[1,5-c]quinazoline, among the compounds described above.
[0025] It is expected that the compound of the present invention is applied to antihypertensive agent, antiallergic agent, antiinflammatory agent, remedy for ischemic heart disease, remedy for leukemia, antipruritic, expectorant, cough remedy, remedy for asthma, analgesic, intraocular-pressure reducing agent and pharmaceutical preparation for prevention or treatment of glaucoma as a compound capable of binding with an adenosine A3 receptor because of its excellent affinity to an adenosine A3 receptor.
[0026] Therefore, the present invention provides a pharmaceutical composition comprising a compound selected from the triazoloquinazoline and pyrazolotriazolopyrimidine derivatives and a pharmaceutically acceptable carrier.
[0027] Also the present invention provides an adenosine A3 receptor affinitive agent comprising a compound selected from the triazoloquinazoline and pyrazolotriazolopyrimidine derivatives as an active ingredient.
[0028] Furthermore, the present invention provides an intraocular-pressure reducing method, which comprises administering an effective amount of a compound selected from the triazoloquinazoline and pyrazolotriazolopyrimidine derivatives to a patient having an enhanced intraocular pressure.
BEST MODE FOR CARRYING OUT THE INEVNTION
[0029] In the present invention, the lower alkyl group includes, for example, straight-chain or branched lower alkyl groups having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, butyl, isobutyl, tert-butyl, pentyl, and hexyl.
[0030] The lower alkoxy group includes, for example, straight-chain or branched lower alkoxy groups having 1 to 6 carbon atoms, such as methoxy, ethoxy, propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy.
[0031] The halogen atom includes fluorine, chlorine, bromine, or iodine. The pyridyl group includes 2-pyridyl, 3-pyridyl or 4-pyridyl.
[0032] The furyl group includes 2-furyl or 3-furyl.
[0033] The thienyl group includes 2-thienyl or 3-thienyl.
[0034] The alkoxycarbonyl lower alkyl group includes C1-C6 lower alkyl groups substituted with a C1-C6 lower alkoxycarbonyl group, such as methoxycarbonylmethyl, ethoxycarbonylmethyl, propoxycarbonylmethyl, butoxycarbonylmethyl, pentyloxycarbonylmethyl, hexyloxycarbonylmethyl, 2-methoxycarbonylethyl, 1-methoxycarbonylethyl, 3-methoxycarbonylpropyl, 4-methoxycarbonylbutyl, 5-methoxycarbonylpentyl, and 6-methoxycarbonylhexyl.
[0035] The carboxy lower alkyl group includes C1-C6 lower alkyl groups substituted with a carboxy group, such as carboxymethyl, 2-carboxyethyl, 1-carboxyethyl, 3-carboxypropyl, 4-carboxybutyl, 5-carboxypentyl, and 6-carboxyhexyl.
[0036] The hydroxy lower alkyl group includes C1-C6 lower alkyl groups substituted with a hydroxy group, such as hydroxymethyl, 2-hydroxyethyl, 1-hydroxyethyl, 3-hydroxypropyl, 4-hydroxybutyl, 5-hydroxypentyl, and 6-hydroxyhexyl.
[0037] The lower alkanoyloxy group includes lower alkanoyloxy groups wherein a C1-C6 straight-chain or branched lower alkyl group is bound to carbonyl carbon, such as acetoxy, propionyloxy, butyryloxy, isobutyryloxy, valeryloxy, pivaloyloxy, hexanoyloxy, and heptanoyloxy.
[0038] The phenyl which optionally has 1 to 3 groups selected from lower alkyl group, halogen atom, phenyl group, halogen-substituted lower alkyl group, hydroxy group, lower alkoxy group, N,N-di lower alkylamino group, lower alkylthio group, lower alkanoyloxy group and nitro group as a substituent includes, for example, phenyl groups which optionally have 1 to 3 substituents selected from C1-C6 alkyl group, halogen atom, phenyl group, halogen-substituted C1-C6 alkyl group, hydroxy group, C1-C6 alkoxy group, N,N-di C1-C6 alkylamino group, C1-C6 alkylthio group, C1-C6 alkanoyloxy group and nitro group as a substituent, such as 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 4-ethylphenyl, 4-propylphenyl, 4-isopropylphenyl, 4-butylphenyl, 4-t-butylphenyl, 4-pentylphenyl, 4-hexylphenyl, 2,3-dimethylphenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl, 3,4-dimethylphenyl, 3,5-dimethylphenyl, 3,4-diethylphenyl, 3,4-dipropylphenyl, 3,4-dibutylphenyl, 3,4-dipentylphenyl, 3,4-dihexylphenyl, 3,4,5-trimethylphenyl, 2,3,4-trimethylphenyl, 2,3,5-trimethylphenyl, 2,3,6-trimethylphenyl, 2,4,6-trimethylphenyl, 2,4,5-trimethylphenyl, 3,4,5-triethylphenyl, 3,4,5-tripropylphenyl, 3,4,5-tributylphenyl, 3,4,5-tripentylphenyl, 3,4,5-trihexylphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 2-iodophenyl, 3-iodophenyl, 4-iodophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,4-dichlorophenyl, 2,3-dichlorophenyl, 3,5-dichlorophenyl, 3,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 2,4-difluorophenyl, 2,4-dibromophenyl, 2,4-diiodophenyl, 3,4,5-trichlorophenyl, 2,4,6-trichlorophenyl, 4-biphenylyl, 3-biphenylyl, 2-biphenylyl, 4-trifluoromethylphenyl, 4-pentafluoroethylphenyl, 4-heptafluoropropylphenyl, 4-nonafluorobutylphenyl, 4-undecafluoropentylphenyl, 4-tridecafluorohexylphenyl, 3-trifluoromethylphenyl, 2-trifluoromethylphenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2,3-dihydroxyphenyl, 2,4-dihydroxyphenyl, 2,5-dihydroxyphenyl, 2,6-dihydroxyphenyl, 3,4-dihydroxyphenyl, 3,5-dihydroxyphenyl, 3,4,5-trihydroxyphenyl, 2,3,4-trihydroxyphenyl, 2,3,5-trihydroxyphenyl, 2,3,6-trihydroxyphenyl, 2,4,6-trihydroxyphenyl, 2,4,5-trihydroxyphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-ethoxyphenyl, 4-propoxyphenyl, 4-butoxyphenyl, 4-pentyloxyphenyl, 4-hexyloxyphenyl, 2,3-dimethoxyphenyl, 2,4-dimethoxyphenyl, 2,5-dimethoxyphenyl, 2,6-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 3,4-diethoxyphenyl, 3,4-dipropoxyphenyl, 3,4-dibutoxyphenyl, 3,4-dipentyloxyphenyl, 3,4-dihexyloxyphenyl, 3,4,5-trimethoxyphenyl, 2,3,4-trimethoxyphenyl, 2,3,5-trimethoxyphenyl, 2,3,6-trimethoxyphenyl, 2,4,6-trimethoxyphenyl, 2,4,5-trimethoxyphenyl, 3,4,5-triethoxyphenyl, 3,4,5-tripropoxyphenyl, 3,4,5-tributoxyphenyl, 3,4,5-tripentyloxyphenyl, 3,4,5-trihexyloxyphenyl, 4-(N,N-dimethylamino)phenyl, 4-(N,N-diethylamino)phenyl, 4-(N,N-dipropylamino)phenyl, 4-(N,N-dibutylamino)phenyl, 4-(N,N-dipentylamino)phenyl, 4-(N,N-dihexylamino)phenyl, 3-(N,N-dimethylamino)phenyl, 2-(N,N-dimethylamino)phenyl, 4-methylthiophenyl, 4-ethylthiophenyl, 4-propylthiophenyl, 4-butylthiophenyl, 4-pentylthiophenyl, 4-hexylthiophenyl, 3-methylthiophenyl, 2-methylthiophenyl, 2-nitrophenyl, 3-nitrophenyl, 4-nitrophenyl, 2,3-dinitrophenyl, 2,4-dinitrophenyl, 2,5-dinitrophenyl, 2,6-dinitrophenyl, 3,4-dinitrophenyl, 3,5-dinitrophenyl, 3,4,5-trinitrophenyl, 2,3,4-trinitrophenyl, 2,3,5-trinitrophenyl, 2,3,6-trinitrophenyl, 2,4,6-trinitrophenyl, 2,4,5-trinitrophenyl, 4-methoxy-3-methylphenyl, 4-methoxy-2-methylphenyl, 3-methoxy-2-methylphenyl, 4-methoxy-3,5-dimethylphenyl, 4-hydroxy-3-methylphenyl, 4-hydroxy-2-methylphenyl, 3-hydroxy-2-methylphenyl, 2-hydroxy-4-methylphenyl, 2-hydroxy-4-methoxyphenyl, 4-hydroxy-3,5-dimethylphenyl, 3,5-di-t-butyl-4-hydroxyphenyl, 4-hydroxy-3,5-dimethoxyphenyl, 3,5-dihydroxy-4-methoxyphenyl, 4-chloro-3-methoxyphenyl, 3-chloro-4-methoxyphenyl, 4-chloro-2-hydroxyphenyl, 4-chloro-3-hydroxyphenyl, 4-chloro-3-methylphenyl, 3-chloro-4-methylphenyl, 4-chloro-3,5-dimethoxyphenyl, 4-chloro-3,5-dimethylphenyl, 4-acetoxyphenyl, 4-propionyloxyphenyl, 4-butyryloxyphenyl, 4-isobutyryloxyphenyl, 4-valeryloxyphenyl, 4-pivaloyloxyphenyl, 4-hexanoyloxyphenyl, 4-heptanoyloxyphenyl, 3,5-diacetoxyphenyl, 3,4-diacetoxyphenyl, 3,4,5-triacetoxyphenyl, and 2,4,6-triacetoxyphenyl, in addition to the phenyl group.
[0039] In case the benzene ring itself is represented as a phenylene group, the benzene ring which is optionally substituted with 1 to 2 groups selected from halogen atom, lower alkyl group, nitro group and lower alkoxy group as a substituent includes, for example, benzene rings which are optionally substituted with 1 to 2 groups selected from halogen atom, C1-C6 alkyl group, nitro group and C1-C6 alkoxy group as a substituent, such as 2-chloro-1,6-phenylene, 3-chloro-1,6-phenylene, 4-chloro-1,6-phenylene, 2-bromo-1,6-phenylene, 3-bromo-1,6-phenylene, 2-iodo-1,6-phenylene, 3-iodo-1,6-phenylene, 2-fluoro-1,6-phenylene, 3-fluoro-1,6-phenylene, 4-fluoro-1,6-phenylene, 2,4-dichloro-1,6-phenylene, 2,3-dichloro-1,6-phenylene, 3,4-dichloro-1,6-phenylene, 2,5-dichloro-1,6-phenylene, 2,4-difluoro-1,6-phenylene, 2,4-dibromo-1,6-phenylene, 2,4-diiodo-1,6-phenylene, 2-methyl-1,6-phenylene, 3-methyl-1,6-phenylene, 4-methyl-1,6-phenylene, 2-ethyl-1,6-phenylene, 2-propyl-1,6-phenylene, 2-isopropyl-1,6-phenylene, 2-butyl-1,6-phenylene, 2-t-butyl-1,6-phenylene, 2-pentyl-1,6-phenylene, 2-hexyl-1,6-phenylene, 2,3-dimethyl-1,6-phenylene, 2,4-dimethyl-1,6-phenylene, 2,5-dimethyl-1,6-phenylene, 3,4-dimethyl-1,6-phenylene, 3,4-diethyl-1,6-phenylene, 3,4-dipropyl-1,6-phenylene, 3,4-dibutyl-1,6-phenylene, 3,4-dipentyl-1,6-phenylene, 3,4-dihexyl-1,6-phenylene, 2-methoxy-1,6-phenylene, 3-methoxy-1,6-phenylene, 4-methoxy-1,6-phenylene, 3-ethoxy-1,6-phenylene, 3-propoxy-1,6-phenylene, 3-butoxy-1,6-phenylene, 3-pentyl-1,6-phenylene, 3-hexyl-1,6-phenylene, 2,3-dimethoxy-1,6-phenylene, 2,4-dimethoxy-1,6-phenylene, 2,5-dimethoxy-1,6-phenylene, 3,4-dimethoxy-1,6-phenylene, 3,4-diethoxy-1,6-phenylene, 3,4-dipropoxy-1,6-phenylene, 3,4-dibutoxy-1,6-phenylene, 3,4-dipentyloxy-1,6-phenylene, 3,4-dihexyloxy-1,6-phenylene, 4-methoxy-3-methyl-1,6-phenylene, 4-methoxy-2-methyl-1,6-phenylene, 3-methoxy-2-methyl-1,6-phenylene, 4-chloro-3-methyl-1,6-phenylene, 4-chloro-2-methyl-1,6-phenylene, 3-chloro-2-methyl-1,6-phenylene, 2-chloro-4-methyl-1,6-phenylene, 2-chloro-4-methoxy-1,6-phenylene, 4-chloro-3-methyl-1,6-phenylene, 4-chloro-3-di-t-butyl-1,6-phenylene, 4-chloro-3-methoxy-1,6-phenylene, 3-chloro-4-methoxy-1,6-phenylene, 4-chloro-3-methoxy-1,6-phenylene, 4-butoxy-3-chloro-1,6-phenylene, 2-chloro-5-methoxy-1,6-phenylene, 2-nitro-1,6-phenylene, 3-nitro-1,6-phenylene, 4-nitro-1,6-phenylene, and 5-nitro-1,6-phenylene, in addition to the 1,6-phenylene group.
[0040] The pyrazole ring which is optionally substituted with a group selected from lower alkyl group, phenyl lower alkyl group, lower alkoxycarbonyl lower alkyl group, carboxy lower alkyl group and hydroxy lower alkyl group as a substituent include, for example, pyrazole rings wherein hydrogen bound to either of nitrogen atom is substituted with the respective groups described above, in addition to the non-substituted pyrazole ring.
[0041] The compound (1a) of the present invention can be prepared by the following reaction scheme-1.
4
[0042] wherein R2 is as defined above; R1a represents a lower alkyl group or a phenyl group; A1 represents a non-substituted pyrazole ring, or a benzene ring which is optionally substituted with 1 to 2 groups selected from halogen atom, lower alkyl group, nitro group and lower alkoxy group as a substituent; and Z represents a lower alkyl group.
[0043] First, a compound represented by the formula (2) is reacted with an orthoester derivative represented by the formula (3) to obtain an imino ester represented by the formula (4). This reaction is carried out by adding the orthoester derivative (3) in an equimolar amount or more relative to the amount of the compound (2) and heating at a temperature within a range from room temperature to reflux temperature for about 10 minutes to 24 hours in the absence of a solvent, or in an inert solvent. As the inert solvent, for example, N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA), dimethyl sulfoxide (DMSO), methanol, diphenyl ether, xylene, and diethylene glycol dimethyl ether can be used.
[0044] The resulting imino ester derivative (4) is reacted with an acyl hydrazine derivative (5), after the imino ester derivative is purified according to a conventional method or not, to obtain the compounds (1a) of the present invention.
[0045] This reaction is carried out by adding the acyl hydrazine derivative (5) in an equimolar amount or more relative to the amount of the imino ester derivative (4) in an inert solvent and heating at a temperature within a range from 50° C. to reflux temperature for about 1 to 50 hours. The inert solvent includes the same solvents as those described above.
[0046] The above-described two-stage reaction can also be carried out simultaneously in the same reaction vessel. For example, the reaction can be carried out by adding the acyl hydrazine derivative (5) in the reaction mixture of the compound (2) and the orthoester derivative (3) and heating in the same manner. In this case, a trace amount of an acid catalyst such as p-toluenesulfonic acid, camphorsulfonic acid, sulfuric acid or trifluoroacetic acid is preferably added in the reaction system.
[0047] The compound (1a′) of the present invention is converted into the compound (1b) of the present invention by the hydrolysis reaction, the reaction with an acid chloride (7) or the cyclization reaction, as shown in the following reaction scheme-2.
5
[0048] wherein R2 and A1 are as defined above; R1a′ represents a lower alkyl group; R1b represents a lower alkyl group, a phenyl group or a lower alkoxycarbonyl lower alkyl group, R2b represents a pyridyl group, a furyl group, a thienyl group, or a phenyl group which optionally have 1 to 3 groups selected from lower alkyl group, halogen atom, phenyl group, halogen-substituted lower alkyl group, hydroxy group, lower alkoxy group, N,N-di lower alkylamino group, lower alkylthio group and nitro group as a substituent; and R2c represents a pyridyl group, a furyl group, a thienyl group, or a phenyl group which optionally have 1 to 3 groups selected from lower alkyl group, halogen atom, phenyl group, halogen-substituted lower alkyl group, lower alkoxy group, N,N-di lower alkylamino group, lower alkylthio group, lower alkanoyloxy group and nitro group as a substituent.
[0049] First, the compound (1a′) is converted into an amine compound (6) by refluxing in an aqueous solution of mineral acid such as hydrochloric acid or sulfuric acid for 5 minutes to 50 hours.
[0050] Then, the amine compound (6) is acylated. This acylation can be carried out by reacting the amine compound (6) with the acid chloride (7) in an amine-based inert solvent such as pyridine, lutidine, triethylamine, or 4-(N,N-dimethylamino)pyridine. In this reaction, the acid chloride (7) is used in an equimolar amount or more and the reaction is completed within about 10 minutes to 3 hours at a temperature within a range from 0° C. to reflux temperature. Since a compound substituted with a plurality of acyl groups may be included sometime in the acylation reaction, the inclusion can optionally be converted into a desired monoacyl compound (8) by refluxing the product, together with a catalytic amount of an alkaline such as anhydrous potassium carbonate or anhydrous sodium carbonate, in an inert solvent such as methanol or ethanol for about 10 minutes to 2 hours.
[0051] Subsequently, the monoacyl compound (8) thus obtained is converted into a compound (1b) of the present invention by the cyclization reaction. The cyclization reaction is carried out by reacting the monoacyl compound (8) with a halogenated trialkylsilane in an inert solvent in the presence of a base.
[0052] As the inert solvent, for example, there can be used aromatic and aliphatic hydrocarbons such as benzene, toluene, xylene, and petroleum ether; ethers such as diethyl ether and tetrahydrofuran; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane; and aliphatic nitrites such as acetonitrile. As the base, for example, tertiary amine such as triethylamine, diisopropylamine, N,N-diethylaniline, N-methyl morpholine, pyridine, or 4-(N,N-dimethylamino)pyridine can be preferably used. As the halogenated trialkylsilane, for example, chlorotrialkylsilane such as chlorotrimethylsilane, chlorotriethylsilane, chloroethyldimethylsilane, chlorodimethylpropylsilane, chlorobutyldimethylsilane, chlorotripropylsilane, tributylchlorosilane, or chloroethylmethylpropylsilane can be preferably used.
[0053] The amount of the halogenated trialkylsilane and base to be used is not specifically limited, but is generally controlled to an equal equivalent weight or more, and preferably from 3- to 20-fold equivalent weight relative to the amount of the monoacyl compound (8). The cyclization reaction is usually completed within about 05 to 100 hours at a temperature within a range from 0 to 100° C.
[0054] Among the starting materials (1a′) in the reaction scheme-2, the cyclization reaction simultaneously proceeds when using the acid chloride (7) in the amount of 3-fold equivalent weight relative to the amount of a compound wherein A1 is a benzene ring which is optionally substituted with 1 to 2 groups selected from halogen atom, lower alkyl group, nitro group and lower alkoxy group as a substituent in the acylation reaction after hydrolysis. Therefore, it becomes unnecessary to carry out the cyclization reaction in that case.
[0055] The compound (1c) of the present invention can be converted into compounds (1d-1) and (1d-2) wherein a substituent is introduced into the pyrazole ring by treating with a halide (9), as shown in the following reaction scheme-3.
6
[0056] wherein R1b is as defined above; R2a represents a pyridyl group, a furyl group, a thienyl group, or a phenyl group which optionally has 1 to 3 groups selected from lower alkyl group, halogen atom, phenyl group, halogen-substituted lower alkyl group, lower alkoxy group, N,N-di lower alkylamino group, lower alkylthio group, lower alkanoyloxy group and nitro group as a substituent; R3 represents a lower alkyl group, a phenyl lower alkyl group, a lower alkoxycarbonyl lower alkyl group, or a hydroxy lower alkyl group, R3a represents a lower alkyl group, a phenyl lower alkyl group, a lower alkoxycarbonyl lower alkyl group, or a trimethylsilyloxy-lower alkyl group; and X represents a halogen atom.
[0057] The conversion is carried out by reacting with an equal equivalent weight or more of a halide (9) in an inert solvent such as DMF, DMA, or DMSO in the presence of an equal equivalent weight or more of an alkali such as anhydrous potassium carbonate or anhydrous sodium carbonate at a temperature within a range from 0° C. to room temperature for 2 to 50 hours.
[0058] When using, as the halide (9), a compound wherein R3a is a trimethylsilyloxy-lower alkyl group, contact of the compound with water in a post treatment causes elimination of the trimethylsilyl group, and thus the trimethylsilyloxy-lower alkyl group is converted into the corresponding hydroxy lower alkyl group.
[0059] The compound (1e) of the present invention can be converted into a compound (if) by hydrolysis, as shown in the reacton scheme-4.
7
[0060] wherein R2 and R2b are as defined above; R1c represents a lower alkyl group, a phenyl group, or a lower alkoxycarbonyl lower alkyl group; R1d represents a lower alkyl group, a phenyl group, or a carboxy lower alkyl group; A2 represents a pyrazole ring which is optionally substituted with a group selected from lower alkyl group, phenyl lower alkyl group, lower alkoxycarbonyl lower alkyl group and hydroxy lower alkyl group as a substituent, or a benzene ring which is optionally substituted with 1 to 2 groups selected from halogen atom, lower alkyl group, nitro group and lower alkoxy group as a substituent; and A3 represents a pyrazole ring which is optionally substituted with a group selected from lower alkyl group, phenyl lower alkyl group, carboxy lower alkyl group and hydroxy lower alkyl group as a substituent, or a benzene ring which which is optionally substituted with 1 to 2 groups selected from halogen atom, lower alkyl group, nitro group and lower alkoxy group as a substituent; provided that the substituents satisfy at least one of (i) to (iii):
[0061] (i) R1c is a lower alkoxycarbonyl lower alkyl group,
[0062] (ii) A2 is a pyrazole ring substituted with a lower alkoxycarbonyl lower alkyl group, and
[0063] (iii) R2 is a phenyl group having a lower alkanoyloxy group.
[0064] The lower alkoxycarbonyl lower alkyl group and/or the lower alkanoyloxy group contained in the compound (1e) of the present invention are hydrolyzed by the hydrolysis reaction to form the corresponding carboxy lower alkyl group and/or hydroxy group, thereby obtaining a compound (1f).
[0065] The reaction is carried out by treating with a solution of an alkaline such as sodium hydroxide or potassium hydroxide in an inert solvent such as methanol or ethanol. The amount of the alkaline is preferably controlled to an equal equivalent weight or more and the reaction is usually completed within about 0.5 to 10 hours at a temperature within a range from about 0° C. to room temperature.
[0066] The desired object in each process of the above reaction schemes 1 to 4 can be easily isolated and purified by a conventional separation means. The separation means includes adsorption chromatography, preparative thin-layer chromatography, recrystallization, solvent extraction or the like.
[0067] When A is a pyrazole ring in the compounds (1) of the present invention prepared as described above, it is considered that the compound includes the following four structural formulas as a tautomer and the tautomer can be represented by any of the structural formulas.
8
[0068] wherein R1 and R2 are as defined above.
[0069] The compounds (1) of the present invention can be formed into pharmaceutically acceptable acid addition salts, and these salts are also included in the present invention. The acid capable of forming these acid salts includes, for example, inorganic acids such as hydrochloric acid, hydrobromic acid, and sulfuric acid; and organic acids such as oxalic acid, fumaric acid, maleic acid, tartaric acid, citric acid, and p-toluenesulfonic acid. The acid addition salts can be formed by a conventional method.
[0070] Among the compounds of the present invention, the pyrazolotriazolopyrimidine derivative can be formed into alkaline metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt and magnesium salt; and copper salts by a conventional method, and these salts can also be included in the present invention.
[0071] The compounds (1) of the present invention are used in the form of a general pharmaceutical preparation by using, together with a suitable non-toxic preparation carrier. The preparation carrier include diluents and excipients, such as fillers, extenders, binders, humectants, disintegrators, surfactants, and lubricants, which are usually used according to the service form of the preparation, and these are appropriately selected and used according to the unit dosage form of the resulting preparation.
[0072] As the unit dosage form of the pharmaceutical preparation using the compound (1) of the present invention, various forms can be selected according to the therapeutic purposes and typical examples thereof include tablets, pills, powders, liquid preparations, suspensions, emulsions, granules, capsules, suppositories, injections (e.g. liquid preparations, suspensions, etc.), ointments, and opthalmic solutions.
[0073] In case of forming into the form of tablets, there can be used, as the preparation carrier, excipients such as lactose, sucrose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silicic acid, and potassium phosphate; binders such as water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethylcellulose, hydroxypropylcellulose, methylcellulose, and polyvinyl pyrrolidone; disintegrators such as sodium carboxymethylcellulose, calcium carboxymethylcellulose, low substituted hydroxypropylcellulose, dried starch, sodium alginate, agar powder, laminaran powder, sodium hydrogencarbonate, and calcium carbonate; surfactants such as polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, and monoglyceride stearate; disintegration inhibitors such as sucrose, stearin, cacao butter, and hydrogenated oil; absorption accelerators such as quaternary ammonium base and sodium lauryl sulfate; humectants such as glycerin and starch; adsorbents such as starch, lactose, kaolin, bentonite, and colloidal silicic acid; and lubricants such as purified talc, stearate, powdered boric acid, and polyethylene glycol.
[0074] If necessary, tablets can be formed into tablets coated with a common coating, for example, sugar-coated tablets, gelatin-coated tablets, enteric coated tablets, film coating tablets, double layered tablets, or mutilayer tablets.
[0075] In case of forming into the form of pills, there can be used, as the preparation carrier, excipients such as glucose, lactose, starch, cacao butter, hardened vegetable oil, kaolin, and talc; binders such as gum arabic, powdered tragacanth, gelatin, and ethanol; and disintegrators such as laminaran and agar.
[0076] In case of forming into the form of suppositories, there can be used, as the preparation carrier, polyethylene glycol, cacao butter, higher alcohol, esters of higher alcohol, gelatin, and semi-synthesized glyceride.
[0077] Capsules are usually prepared by mixing the compound (1) of the present invention with various pharmaceutical preparations and filling a hard gelatin capsule or a soft gelatin capsule with the mixture.
[0078] In case of preparing as injections such as liquid preparations, emulsions or suspension, these are preferably sterilized and are isotonic with blood. In case of forming into the form of injections, there can be used, as the diluent, water, ethyl alcohol, macrogol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, or polyoxyethylene sorbitan fatty acid esters. In this case, salt, glucose or glycerin may be contained in an enough amount to prepare an isotonic solution and common solubilizers, buffer agents or soothing agents may also be added.
[0079] If necessary, the pharmaceutical preparation further contains colorants, preservatives, perfumes, flavors, sweeteners, or other drugs.
[0080] In case of forming into the form of ointments such as paste, cream, or gel, there can be used, as the diluent, white soft paraffin, paraffin, glycerin, cellulose derivative, polyethylene glycol, silicon, and bentonite.
[0081] The amount of the compound (1) of the present invention to be incorporated in the pharmaceutical preparation is not specifically limited and appropriately selected from a wide range, but is preferably within a range from about 1 to 85% by weight based on the pharmaceutical preparation.
[0082] Eye drops are usually prepared by a conventional method using sterilized distilled water as a base; buffer agents such as sodium dihydrogenphosphate and sodium monohydrogenphosphate; isotonizing agents such as sodium chloride and concentrated glycerin; buffering agents such as sodium phosphate and sodium acetate; surfactants such as polyoxyethylene sorbitan monooleatae, polyoxy 40 stearate and polyocyethylene hardened castor oil; solubilizers such as sodium carboxymethylcellulose, polyoxyethylene lauryl ether, polyoxyethylene oleyl ether, polyethylene glycol monolaurate, and polyethylene glycol monooleate; stabilizers such as sodium citrate and sodium edetate; and antiseptics such as benzatonium chloride, chlorobutanol, benzalkonium chloride, and paraben. The pH is not specifically limited as far as it is within an ophthalmologically acceptable range, and is preferably within a range from 4 to 8.
[0083] The administration method of the pharmaceutical preparation is not specifically limited, but is appropriately decided according to the form of preparations, age of patients, sex and other conditions, or conditions of diseases. For example, tablets, pills, liquid preparations, suspensions, granules and capsules are orally administered, while injections are intravenously administered alone or in combination with a conventional replenisher such as glucose or amino acid, or intramascularly, intracutaneously, subctaneously or intraperitoneally administered alone, if necessary. Furthermore, suppositories are intrarectally administered.
[0084] The dose of the pharmaceutical preparation varies depending on the administration method, age of patients, sex and other conditions, or conditions of diseases, but a dairy dose of the compound (1) of the present invention is usually within a range from about 05 to 20 mg/kg, and preferably from about 1 to 10 mg/kg. The pharmaceutical preparation can be administered 1 to 4 times per day.
INDUSTRIAL APPLICABILITY
[0085] It is expected that the compound of the present invention is applied to antihypertensive agent, antiallergic agent, antiinflammatory agent, remedy for ischemic heart disease, remedy for leukemia, antipruritic, expectorant, cough remedy, remedy for asthma, analgesic, intraocular-pressure reducing agent and pharmaceutical preparation for prevention or treatment of glaucoma as a compound capable of binding with an adenosine A3 receptor because of its excellent affinity to an adenosine A3 receptor.
EXAMPLES
[0086] The following Examples further illustrate the compounds of the present invention in detail.
Example 1
[0087] Preparation of 5-methyl-2-phenylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0088] 0.5 g of 3-amino-4-cyanopyrazole was suspended in 3 mL of DMF and 0.61 g of trimethyl orthoacetate and 1 mg of p-toluenesulfonic acid (monohydrate), followed by stirring at 80° C. for 45 minutes. To the reaction solution, 0.69 g of N-benzoyl hydrazine was further added, and then the mixture was refluxed for 14 hours. After the completion of the reaction, 10 mL of water was added when the reaction solution was cooled to about 100° C., followed by cooling to room temperature. The deposited crystal was collected by filtration and then washed with hydrous ethanol to obtain 0.91 g of a desired compound as a crystal.
[0089] Melting point: >280° C.
Examples 2 to 86
[0090] In the same manner as in Example 1, the following compounds were prepared.
[0091] (Example 2) 5-ethyl-2-phenylpyrazole[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0092] Melting point: 274-275.5° C.
[0093] (Example 3) 2-phenyl-5-propylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0094] Melting point: 247 to 248° C.
[0095] (Example 4) 5-n-butyl-2-phenylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0096] Melting point: 214-215° C.
[0097] (Example 5) 5-n-butyl-2-(4-fluorophenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0098] Melting point: 228 to 230° C.
[0099] (Example 6) 5-n-butyl-2-(4-chlorophenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0100] Melting point: 231-233° C.
[0101] (Example 7) 2-(4-bromophenyl)-5-n-butylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0102] Melting point: 257-258° C.
[0103] (Example 8) 5-n-butyl-2-(4-methylphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0104] Melting point: 242 to 243%
[0105] (Example 9) 5-n-butyl-2-(4-t-butylphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0106] Melting point: 197-199° C.
[0107] (Example 10) 5-n-butyl-2-(4-trifluoromethylphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0108] Melting point: 234-235° C.
[0109] (Example 11) 2-(4-biphenylyl)-5-n-butylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0110] Melting point: 249-250° C.
[0111] (Example 12) 5-n-butyl-2-(4-hydroxyphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0112] Melting point: >280° C.
[0113] (Example 13) 5-n-butyl-2-(4-ethoxyphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0114] Melting point: 204-205.5° C.
[0115] (Example 14) 5-n-butyl-2-(4-propoxyphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0116] Melting point: 191-192° C.
[0117] (Example 15) 5-n-butyl-2-(3,4,5-trimethoxyphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0118] Melting point: 259-262° C.
[0119] (Example 16) 5-n-butyl-2-[4-(N,N-dimethylamino)phenyl]pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0120] Melting point: >240% C (with decomposition)
[0121] (Example 17) 5-n-butyl-2-(4-nitrophenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0122] Melting point: 279-280.5° C.
[0123] (Example 18) 5-n-butyl-2-(3-pyridyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0124] Melting point: 217-219° C.
[0125] (Example 19) 5-n-butyl-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0126] Melting point: 253-254.5° C.
[0127] (Example 20) 5-n-butyl-2-(2-thienyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0128] Melting point: 214-216° C.
[0129] (Example 21) 2-phenyl-5-propyl-1,2,4-triazolo[1,5-c]quinazoline
[0130] Melting point: 143-144° C.
[0131] (Example 22) 5-n-butyl-2-phenyl-1,2,4-triazolo[1,5-c]quinazoline
[0132] Melting point: 133-135° C.
[0133] (Example 23) 5-n-butyl-2-(4-fluorophenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0134] Melting point: 167-169° C.
[0135] (Example 24) 5-n-butyl-2-(2-chlorophenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0136] Melting point: 104.5-105.55° C.
[0137] (Example 25) 5-n-butyl-2-(3-chlorophenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0138] Melting point: 129-131° C.
[0139] (Example 26) 5-n-butyl-2-(4-chlorophenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0140] Melting point: 160-161° C. (Example 27) 2-(4-bromophenyl)-5-n-butyl-1,2,4-triazolo[1,5-c]quinazoline
[0141] Melting point: 169-171° C. (Example 28) 5-n-butyl-2-(4-methylphenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0142] Melting point: 153-154° C.
[0143] (Example 29) 5-n-butyl-2-(4-t-butylphenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0144] Melting point: 106-108° C.
[0145] (Example 30) 5-n-butyl-2-(4-trifluoromethylphenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0146] Melting point: 157-159° C.
[0147] (Example 31) 2-(4-biphenylyl)-5-n-butyl-1,2,4-triazolo[1,5-c]quinazoline
[0148] Melting point: 159-161° C.
[0149] (Example 32) 5-n-butyl-2-(4-hydroxyphenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0150] Melting point: 234-235.5° C.
[0151] (Example 33) 5-n-butyl-2-(2-methoxyphenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0152] Melting point: 106.5-107.5° C.
[0153] (Example 34) 5-n-butyl-2-(4-methoxyphenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0154] Melting point: 126-128° C.
[0155] (Example 35) 5-n-butyl-2-(4-ethoxyphenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0156] Melting point: 149-150° C.
[0157] (Example 36) 5-n-butyl-2-(4-propoxyphenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0158] Melting point: 128-129° C.
[0159] (Example 37) 5-n-butyl-2-(3,4,5-trimethoxyphenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0160] Melting point: 130-133° C.
[0161] (Example 38) 5-n-butyl-2-[4-(N,N-dimethylamino)phenyl]-1,2,4-triazolo[1,5-c]quinazoline
[0162] Melting point: 148.5-150° C.
[0163] (Example 39) 5-n-butyl-2-(4-nitrophenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0164] Melting point: 194-195° C.
[0165] (Example 40) 5-n-butyl-2-(3-pyridyl)-1,2,4-triazolo[1,5-c]quinazoline
[0166] Melting point: 140-141.5° C.
[0167] (Example 41) 5-n-butyl-2-(2-furyl)-1,2,4-triazolo[1,5-c]quinazoline
[0168] Melting point: 110-111.5° C.
[0169] (Example 42) 5-n-butyl-2-(2-thienyl)-1,2,4-triazolo[1,5-c]quinazoline
[0170] Melting point: 147-149.5° C.
[0171] (Example 43) 5-n-butyl-10-fluoro-2-phenyl-1,2,4-triazolo[1,5-c]quinazoline
[0172] Melting point: 123-124° C.
[0173] (Example 44) 5-n-butyl-10-chloro-2-phenyl-1,2,4-triazolo[1,5-c]quinazoline
[0174] Melting point: 122-123° C.
[0175] (Example 45) 5-n-butyl-9-chloro-2-phenyl-1,2,4-triazolo[1,5-c]quinazoline
[0176] Melting point: 110-113° C.
[0177] (Example 46) 5-n-butyl-8-chloro-2-phenyl-1,2,4-triazolo[1,5-c]quinazoline
[0178] Melting point: 143-144° C.
[0179] (Example 47) 9-bromo-5-n-butyl-2-phenyl-1,2,4-triazolo[1,5-c]quinazoline
[0180] Melting point: 129.5-132.5° C.
[0181] (Example 48) 5-n-butyl-8,9-dimethoxy-2-phenyl-1,2,4-triazolo[1,5-c]quinazoline
[0182] Melting point: 150-152° C.
[0183] (Example 49) 5-n-butyl-10-methyl-2-phenyl-1,2,4-triazolo[1,5-c]quinazoline
[0184] Melting point: 123-124° C.
[0185] (Example 50) 5-n-butyl-8-methyl-2-phenyl-1,2,4-triazolo[1,5-c]quinazoline
[0186] Melting point: 136.5-138° C.
[0187] (Example 51) 5-n-butyl-2-(2-chlorophenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0188] Melting point: 206-207° C.
[0189] (Example 52) 5-n-butyl-2-(3-chlorophenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0190] Melting point: 240-242.5° C.
[0191] (Example 53) 5-n-butyl-2-(2-methoxyphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0192] Melting point: 157-160° C.
[0193] (Example 54) 5-n-butyl-2-(3-methoxyphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0194] (Example 55) 5-n-butyl-2-(4-methoxyphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0195] Melting point: 206-208° C.
[0196] (Example 56) 5-n-butyl-2-(4-methylthiophenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0197] Melting point: 204-205° C.
[0198] (Example 57) 5-n-butyl-2-(3-methoxyphenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0199] Melting point: 118-119° C.
[0200] (Example 58) 5-n-butyl-2-(4-methylthiophenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0201] Melting point: 140.5-141.5° C.
[0202] (Example 59) 2,5-diphenylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0203] Melting point: 272.5-275° C.
[0204] (Example 60) 2-(4-methylphenyl)-5-n-propylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0205] Melting point: 274-275° C.
[0206] (Example 61) 5-n-butyl-2-(4-ethylphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0207] Melting point: 208.5-210° C.
[0208] (Example 62) 5-n-butyl-2-(4-n-propylphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0209] Melting point: 207.5-209° C.
[0210] (Example 63) 5-ethyl-2-(4-methoxyphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0211] Melting point: 274-277° C.
[0212] (Example 64) 2-(4-chlorophenyl)-5-ethylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0213] Melting point: >280° C.
[0214] (Example 65) 5-ethyl-2-(4-methylphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0215] Melting point: >280° C.
[0216] (Example 66) 2-(4-bromophenyl)-5-ethyl-1,2,4-triazolo[1,5-c]quinazoline
[0217] Melting point: 197-198° C.
[0218] (Example 67) 5-ethyl-2-(4-fluorophenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0219] Melting point: 195-196° C.
[0220] (Example 68) 2-(4-chlorophenyl)-5-ethyl-1,2,4-triazolo[1,5-c]quinazoline
[0221] Melting point: 197-198° C.
[0222] (Example 69) 5-ethyl-2-(4-methylphenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0223] Melting point: 147-148′ (Example 70) 5-ethyl-2-(4-hydroxyphenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0224] Melting point: >280° C.
[0225] (Example 71) 5-ethyl-2-(4-methoxyphenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0226] Melting point: 167.5-168° C.
[0227] (Example 72) 2-(4-ethoxyphenyl)-5-ethyl-1,2,4-triazolo[1,5-c]quinazoline
[0228] Melting point: 153-154° C.
[0229] (Example 73) 9-chloro-2-phenyl-5-n-propyl-1,2,4-triazolo[1,5-c]quinazoline
[0230] Melting point: 140.5-141.5° C.
[0231] (Example 74) 5-n-butyl-9-chloro-2-(4-fluorophenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0232] Melting point: 147.5-150° C.
[0233] (Example 75) 5-n-butyl-9-chloro-2-(4-chlorophenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0234] Melting point: 138.5-140° C.
[0235] (Example 76) 2-(4-bromophenyl)-5-n-butyl-9-chloro-1,2,4-triazolo[1,5-c]quinazoline
[0236] Melting point: 158-159.5° C.
[0237] (Example 77) 5-n-butyl-9-chloro-2-(4-methylphenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0238] Melting point: 141-143° C.
[0239] (Example 78) 5-n-butyl-9-chloro-2-(4-methoxyphenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0240] Melting point: 124-125° C.
[0241] (Example 79) 8-chloro-2-phenyl-5-n-propyl-1,2,4-triazolo[1,5-c]quinazoline
[0242] Melting point: 147-149° C.
[0243] (Example 80) 5-n-butyl-8-chloro-2-(4-fluorophenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0244] Melting point: 185.5-186.5° C.
[0245] (Example 81) 5-n-butyl-8-chloro-2-(4-chlorophenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0246] Melting point: 153.5-155° C. (Example 82) 2-(4-bromophenyl)-5-n-butyl-8-chloro-1,2,4-triazolo[1,5-c]quinazoline
[0247] Melting point: 150-151° C.
[0248] (Example 83) 5-n-butyl-8-chloro-2-(4-methylphenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0249] Melting point: 134-134.5° C.
[0250] (Example 84) 5-n-butyl-8-chloro-2-(4-methoxyphenyl)-1,2,4-triazolo[1,5-c]quinazoline
[0251] Melting point: 138.5-139.5° C.
[0252] (Example 85) 5-n-butyl-9-nitro-2-phenyl-1,2,4-triazolo[1,5-c]quinazoline
[0253] Melting point: 205.5-206° C.
[0254] (Example 86) 9-chloro-2-(4-chlorophenyl)-5-ethyl-1,2,4-triazolo[1,5-c]quinazoline
[0255] Melting point: 213-214° C.
Example 87
[0256] Preparation of 5-n-pentyl-2-phenylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0257] 3 g of the compound (5-ethyl-2-phenylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine) obtained in Example 2 was dissolved in a mixed solution of 6 ml of concentrated hydrochloric acid and 30 ml of ethanol, followed by heating at reflux for 20 minutes. To the reaction solution, 60 ml of water was added and, after cooling to room temperature, the pH of the solution was adjusted to 8 by adding 25% aqueous ammonia. The deposited crystal was collected by filtration to obtain 2.2 g of 3-(3-aminopyrazol-4-yl)-5-phenyl-1,2,4-triazole.
[0258] To a solution of 0.5 g of the crystal in 5 ml of pyridine, a solution of 0.89 g of hexanoyl chloride in 5 ml of dichloromethane was added dropwise at 0° C. and, after stirring at 0° C. for 10 minutes, then at room temperature for 30 minutes, the mixture was heated at reflux for 15 minutes. The reaction solution was cooled to room temperature and the deposited crystal was collected by filtration to obtain 0.45 g of 3-[3-(N-hexanoylamino)pyrazol-4-yl]-5-phenyl-1,2,4-triazole (250-251° C.).
[0259] Subseqeuntly, 0.4 g of the crystal thus obtained was suspended in 3 ml of acetonitrile and 1.0 ml of diisopropylethylamine and 0.78 ml of chlorotrimethylsilane were added, followed by heating at reflux for 26 hours. The reaction solution was cooled to room temperature, diluted with chloroform and then washed in turn with water and saturated saline. After the solvent was distilled off, the deposited crystal was washed with heated 50% methanol to obtain 0.26 g of a desired compound as a crystal.
[0260] Melting point: 200-201° C.
Examples 88 to 107
[0261] In the same manner as in Example 87, the following compounds were prepared.
[0262] (Example 88) 5-n-hexyl-2-phenylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0263] Melting point: 207-208° C. (Example 89) methyl 4-[2-phenylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-yl]butyrate
[0264] Melting point: 186-187° C.
[0265] (Example 90) methyl 4-[2-(4-methoxyphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-yl]butyrate
[0266] Melting point: 187.5-188.5° C.
[0267] (Example 91) methyl 4-[2-(4-chlorophenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-yl]butyrate
[0268] Melting point: 194.5-196.5° C.
[0269] (Example 92) methyl 4-[2-(4-methylphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-yl]butyrate
[0270] Melting point: 196.5-197° C.
[0271] (Example 93) 5-n-pentyl-2-phenyl-1,2,4-triazolo[1,5-c]quinazoline
[0272] Melting point: 118-118.5° C.
[0273] (Example 94) 5-n-hexyl-2-phenyl-1,2,4-triazolo[1,5-c]quinazoline
[0274] Melting point: 92-93° C.
[0275] (Example 95) 2-(4-fluorophenyl)-5-n-pentyl-1,2,4-triazolo[1,5-c]quinazoline
[0276] Melting point: 133.5-134° C.
[0277] (Example 96) methyl 4-(2-phenyl-1,2,4-triazolo[1,5-c]quinazolin-5-yl)butyrate
[0278] Melting point: 118.5-119.5° C.
[0279] (Example 97) methyl 4-[2-(4-bromophenyl)-1,2,4-triazolo[1,5-c]quinazolin-5-yl]butyrate
[0280] Melting point: 125-126° C.
[0281] (Example 98) methyl 4-[2-(4-fluorophenyl)-1,2,4-triazolo[1,5-c]quinazolin-5-yl]butyrate
[0282] Melting point: 167-168° C.
[0283] (Example 99) methyl 4-[2-(4-chlorophenyl)-1,2,4-triazolo[1,5-c]quinazolin-5-yl]butyrate
[0284] Melting point: 128-129° C.
[0285] (Example 100) methyl 4-[2-(4-methylphenyl)-1,2,4-triazolo[1,5-c]quinazolin-5-yl]butyrate
[0286] Melting point: 120.5-121.5° C.
[0287] (Example 101) 2-(4-methylphenyl)-5-n-pentyl-1,2,4-triazolo[1,5-c]quinazoline
[0288] Melting point: 129.5-131° C.
[0289] (Example 102) 2-(4-bromophenyl)-5-n-pentyl-1,2,4-triazolo[1,5-c]quinazoline
[0290] Melting point: 133-134° C.
[0291] (Example 103) 2-(4-chlorophenyl)-5-n-pentyl-1,2,4-triazolo[1,5-c]quinazoline
[0292] Melting point: 118-119.5° C.
[0293] (Example 104) methyl 4-[9-chloro-2-(4-chlorophenyl)-1,2,4-triazolo[1,5-c]quinazolin-5-yl]butyrate
[0294] Melting point: 145-146.5° C.
[0295] (Example 105) 2-(4-methoxyphenyl)-5-n-pentyl-1,2,4-triazolo[1,5-c]quinazoline
[0296] Melting point: 123-125° C.
[0297] (Example 106) 2-(4-ethoxyphenyl)-5-n-pentyl-1,2,4-triazolo[1,5-c]quinazoline
[0298] Melting point: 116-117° C.
[0299] (Example 107) 2-(4-hexanoyloxyphenyl)-5-n-pentyl-1,2,4-triazolo[1,5-c]quinazoline
[0300] Melting point: 805-82° C.
Examples 108 and 109
[0301] Preparation of 5-n-butyl-2-(4-fluorophenyl)-7-methylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (Example 108) and 5-n-butyl-2-(4-fluorophenyl)-8-methylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (Example 109)
[0302] 0.60 g of the compound (5-n-butyl-2-(4-fluorophenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine) obtained in Example and 0.32 g of anhydrous potassium carbonate were suspended in 10 ml of DMF, followed by stirring at room temperature for one hours, then at 50° C. for 15 minutes. The mixed solution was cooled to 0° C. and 0.30 g of methyl iodide was added dropwise, followed by stirring at 0° C. for one hours, then at room temperature for 16 hours. To the reaction solution, iced water was added and the deposited crystal was purified by silica gel column chromatography (as an eluent, chloroform was used and then a mixture of chloroform and methanol (50:1) was used) to obtain 0.36 g of a desired 7-methyl derivative (melting point: 150.5-151.5° C.) from the first fraction and 0.19 g of a 8-methyl derivative (melting point: 205.5-206.5° C.) from the second fraction.
Examples 110 to 146
[0303] In the same manner as in Examples 108 and 109, the following compounds were prepared.
[0304] (Example 110) 5-n-butyl-7-methyl-2-phenylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0305] Melting point: 172-173° C.
[0306] (Example 111) 5-n-butyl-8-methyl-2-phenylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0307] Melting point: 184-185° C.
[0308] (Example 112) 5-n-butyl-2-phenyl-7-n-propylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0309] Melting point: 100.5-101.5° C.
[0310] (Example 113) 5-n-butyl-2-phenyl-8-n-propylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0311] Melting point: 107-108° C.
[0312] (Example 114) 5-n-butyl-7-ethyl-2-phenylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0313] Melting point: 146-147° C.
[0314] (Example 115) 5-n-butyl-8-ethyl-2-phenylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0315] Melting point: 122.5-123° C.
[0316] (Example 116) 7-benzyl-5-n-butyl-2-phenylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0317] Melting point: 108-109° C.
[0318] (Example 117) 8-benzyl-5-n-butyl-2-phenylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0319] Melting point: 159-160° C.
[0320] (Example 118) 2-(4-chlorophenyl)-5-n-butyl-7-methylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0321] Melting point: 147.5-148.5° C.
[0322] (Example 119) 2-(4-chlorophenyl)-5-n-butyl-8-methylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0323] Melting point: 203.5-205° C.
[0324] (Example 120) 5-n-butyl-7-methyl-2-(4-methylphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0325] Melting point: 156-157° C.
[0326] (Example 121) 5-n-butyl-8-methyl-2-(4-methylphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0327] Melting point: 180-181° C.
[0328] (Example 122) 5-n-butyl-2-(4-methylphenyl)-7-n-propylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0329] Melting point: 113-113.5° C.
[0330] (Example 123) 5-n-butyl-2-(4-methylphenyl)-8-n-propylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0331] Melting point: 101.5-103.5° C.
[0332] (Example 124) 5-n-butyl-2-(4-fluorophenyl)-7-n-propylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0333] Melting point: 105.5-106° C.
[0334] (Example 125) 5-n-butyl-2-(4-fluorophenyl)-8-n-propylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0335] Melting point: 106.5-107.5° C.
[0336] (Example 126) 5-n-butyl-2-(4-chlorophenyl)-7-n-propylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0337] Melting point: 131.5-132° C.
[0338] (Example 127) 5-n-butyl-2-(4-chlorophenyl)-8-n-propylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0339] Melting point: 137-138° C.
[0340] (Example 128) ethyl 2-(5-n-butyl-2-phenylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-7-yl)acetate
[0341] Melting point: 131.5-132.5° C.
[0342] (Example 129) ethyl 2-(5-n-butyl-2-phenylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-8-yl)acetate
[0343] Melting point: 136-137° C.
[0344] (Example 130) ethyl 2-[5-n-butyl-2-(4-fluorophenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-7-yl]acetate
[0345] Melting point: 139.5-140.5° C.
[0346] (Example 131) ethyl 2-[5-n-butyl-2-(4-fluorophenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-8-yl]acetate
[0347] Melting point: 164-165° C.
[0348] (Example 132) 5-n-butyl-7-(2-hydroxyethyl)-2-phenylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0349] Melting point: 132-133° C.
[0350] (Example 133) 5-n-butyl-8-(2-hydroxyethyl)-2-phenylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0351] Melting point: 160.5-162° C.
[0352] (Example 134) 5-n-butyl-2-(4-fluorophenyl)-7-(2-hydroxyethyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0353] Melting point: 150.5-151.5° C.
[0354] (Example 135) 5-n-butyl-2-(4-fluorophenyl)-8-(2-hydroxyethyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0355] Melting point: 202-203° C.
[0356] (Example 136) 5-n-butyl-7-(2-hydroxyethyl)-2-(4-methylphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0357] Melting point: 134-136° C.
[0358] (Example 137) 5-n-butyl-8-(2-hydroxyethyl)-2-(4-methylphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0359] Melting point: 171-173° C.
[0360] (Example 138) 5-n-butyl-2-(4-chlorophenyl)-7-(2-hydroxyethyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0361] Melting point: 164-164.5° C.
[0362] (Example 139) 5-n-butyl-2-(4-chlorophenyl)-8-(2-hydroxyethyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0363] Melting point: 189-190.5° C.
[0364] (Example 140) 5-n-butyl-7-(2-hydroxyethyl)-2-(4-methoxyphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0365] Melting point: 147.5-148.5° C.
[0366] (Example 141) 5-n-butyl-8-(2-hydroxyethyl)-2-(4-methoxyphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0367] Melting point: 178-179° C.
[0368] (Example 142) 5-n-butyl-8-ethyl-2-(4-methoxyphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0369] Melting point: 127-128° C.
[0370] (Example 143) 5-n-butyl-8-ethyl-2-(4-methylphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0371] Melting point: 128-129° C.
[0372] (Example 144) 5-n-butyl-8-ethyl-2-(4-fluorophenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0373] Melting point: 146-147° C.
[0374] (Example 145) 5-n-butyl-2-(4-chlorophenyl)-8-ethylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0375] Melting point: 141-142° C.
[0376] (Example 146) 5-n-butyl-2-(4-methoxyphenyl)-8-n-propylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
[0377] Melting point: 112-112.5° C.
Example 147
[0378] Preparation of 4-(2-phenylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-yl)butyric Acid
[0379] 0.15 g of the compound (methyl 4-[2-phenylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-yl]butyrate) obtained in Example 89 was suspended in 3 ml of ethanol and 0.89 ml of a 5% aqueous sodium hydroxide solution was added, followed by stirring at room temperature for 4 hours. The reaction solution was diluted with 10 ml of water and then acidified by adding hydrochloric acid. The deposited crystal was collected by filtration and then recrystallized from hydrous ethanol to obtain 0.13 g of a desired compound as a crystal (melting point: 261.5-262.5° C.).
Examples 148 to 157
[0380] In the same manner as in Example 147, the following compounds were prepared.
[0381] (Example 148) 4-[2-(4-methoxyphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-yl]butyric acid
[0382] Melting point: 247.5-249° C.
[0383] (Example 149) 4-[2-(4-chlorophenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-yl]butyric acid
[0384] Melting point: 253.5-255.5° C.
[0385] (Example 150) 4-[2-(4-methylphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-yl]butyric acid
[0386] Melting point: 249-251° C.
[0387] (Example 151) 2-(5-n-butyl-2-phenylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-7-yl)acetic acid
[0388] Melting point: 271-272.5° C.
[0389] (Example 152) 2-(5-n-butyl-2-phenylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-8-yl)acetic acid
[0390] Melting point: >281° C. (with decomposition)
[0391] (Example 153) 4-(2-phenyl-1,2,4-triazolo[1,5-c]quinazolin-5-yl)butyric acid
[0392] Melting point: 211-211.5° C.
[0393] (Example 154) 4-[2-(4-bromophenyl)-1,2,4-triazolo[1,5-c]quinazolin-5-yl]butyric acid
[0394] Melting point: 219-220° C.
[0395] (Example 155) 4-[2-(4-fluorophenyl)-1,2,4-triazolo[1,5-c]quinazolin-5-yl]butyric acid
[0396] Melting point: 225-226° C.
[0397] (Example 156) 4-[2-(4-chlorophenyl)-1,2,4-triazolo[1,5-c]quinazolin-5-yl]butyric acid
[0398] Melting point: 227-228° C.
[0399] (Example 157) 2-(4-hydroxyphenyl)-5-n-pentyl-1,2,4-triazolo[1,5-c]quinazoline
[0400] Melting point: 214-215° C.
[0401] Data of 1H-NMR spectrum (δ:ppm) of the compounds of the above respective Examples are shown below. Dimethyl sulfoxide-d6 (DMSO-d6) or chloroform-d (CDCl3) was used as a solvent in the measurement and tetramethylsilane was used as an internal reference.
DMSO-d6
[0402] 2.97 (3H, s), 7.5-7.6 (3H, m), 8.2-8.3 (2H, m), 8.57 (1H, bs).
DMSO-d6
[0403] 1.45 (3H, t, J=7.4), 3.37 (2H, q, J=7.4), 7.5-7.6 (3H, m), 8.2-8.3 (2H, m), 8.56 (1H, bs).
DMSO-d6
[0404] 1.07 (3H, t, J=7.4), 1.9-2.1 (2H, m), 3.3-3.4 (2H, m), 7.5-7.7 (3H, m), 8.2-8.4 (2H, m), 8.56 (1H, bs).
DMSO-d6
[0405] 0.99 (3H, t, J=7.2), 1.4-1.6 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 7.5-7.6 (3H, m), 8.2-8.3 (2H, m), 8.56 (1H, bs).
DMSO-d6
[0406] 0.98 (3H, t, J=7.4), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 7.40 (2H, t, J=8.8), 8.29 (2H, dd, J=5.5, 8.8), 8.55 (1H, bs).
DMSO-d6
[0407] 0.98 (3H, t, J=7.4), 1.4-1.5 (2H, m), 1.8-2.0 (2H, m), 3.3-3.4 (2H, m), 7.75 (2H, d, J=8.5), 8.16 (2H, d, J=8.5), 8.54 (1H, bs).
DMSO-d6
[0408] 0.98 (3H, t, J=7.3), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 7.63 (2H, d, J=8.6), 8.24 (2H, d, J=8.6), 8.55 (1H, bs).
DMSO-d6
[0409] 0.98 (3H, t, J=7.3), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 2.40 (3H, s), 3.3-3.4 (2H, m), 7.37 (2H, d, J=8.1), 8.14 (2H, d, J=8.1), 8.54 (1H, bs).
DMSO-d6
[0410] 0.98 (3H, t, J=7.4), 1.34 (9H, s), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 7.58 (2H, d, J=8.5), 8.17 (2H, d, J=8.5), 8.55 (1H, bs).
DMSO-d6
[0411] 0.99 (3H, t, J=7.3), 1.4-1.6 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 7.91 (2H, d, J=8.3), 8.42 (2H, d, J=8.3), 8.56 (1H, bs).
DMSO-d6
[0412] 0.99 (3H, t, J=7.3), 1.4-1.6 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 7.4-7.6 (3H, m), 7.77 (2H, d, J=7.3), 7.87 (2H, d, J=8.4), 8.33 (2H, d, J=8.4), 8.57 (1H, bs).
DMSO-d6
[0413] 0.98 (3H, t, J=7.3), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 6.94 (2H, d, J=8.7), 8.09 (2H, d, J=8.7), 8.52 (1H, bs).
DMSO-d6
[0414] 0.98 (3H, t, J=7.4), 1.37 (3H, t, J=6.9), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 4.12 (2H, q, J=7.0), 7.08 (2H, d, J=8.9), 8.16 (2H, d, J=8.9), 8.53 (1H, bs).
DMSO-d6
[0415] 0.98 (3H, t, J=7.5), 1.01 (3H, t, J=7.5), 1.4-1.6 (2H, m), 1.7-1.8 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 4.01 (2H, t, J=6.6), 7.09 (2H, d, J=8.7), 8.16 (2H, d, J=8.7), 8.52 (1H, bs).
DMSO-d6
[0416] 0.99 (3H, t, J=7.4), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 3.76 (3H, s), 3.91 (6H, s), 7.52 (2H, s), 8.56 (1H, bs).
DMSO-d6
[0417] 0.98 (3H, t, J=7.3), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.01 (6H, s), 3.3-3.4 (2H, m), 6.83 (2H, d, J=8.9), 8.06 (2H, d, J=8.9), 8.50 (1H, bs).
DMSO-d6
[0418] 0.99 (3H, t, J=7.3), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 8.39 (2H, d, J=9.0), 8.46 (2H, d, J=9.0), 8.58 (1H, bs).
DMSO-d6
[0419] 0.99 (3H, t, J=7.5), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 7.61 (1H, dd, J=5.0, 7.9), 8.5-8.6 (2H, m), 8.75 (1H, dd, J=1.7, 5.0), 9.40 (1H, d, J=2.1).
DMSO-d6
[0420] 0.98 (3H, t, J=7.4), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 7.47 (1H, dd, J=1.8, 3.4), 7.28 (1H, dd, J=0.6, 3.4), 7.96 (1H, dd, J=0.6, 1.8), 8.53 (1H, bs).
DMSO-d6
[0421] 0.98 (3H, t, J=7.5), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 7.25 (1H, dd, J=3.3, 5.0), 7.79 (1H, dd, J=1.2, 5.0), 7.89 (1H, dd, J=1.2, 3.3), 8.55 (1H, bs).
CDCl3
[0422] 1.16 (3H, t, J=7.4), 2.0-2.1 (2H, m), 3.4-3.5 (2H, m), 7.5-7.6 (3H, m), 7.6-7.7 (1H, m), 7.8-7.9 (1H, m), 8.01 (1H, bd, J=8.2), 8.3-8.4 (2H, m), 8.58 (1H, dd, J=1.1, 8.0).
DMSO-d6
[0423] 0.99 (3H, t, J=7.3), 1.4-1.6 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 7.5-7.6 (3H, m), 7.7-7.8 (1H, m), 7.9-8.0 (1H, m), 8.02 (1H, bd, J=8.0), 8.2-8.3 (2H, m), 8.47 (1H, dd, J=0.9, 7.9).
CDCl3
[0424] 1.04 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.4-3.5 (2H, m), 7.21 (2H, t, J=8.7), 7.6-7.7 (1H, m), 7.8-7.9 (1H, m), 8.01 (1H, bd, J=8.2), 8.38 (2H, dd, J=5.4, 8.7), 8.55 (1H, dd, J=1.1, 8.0).
CDCl3
[0425] 1.03 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.4-3.5 (2H, m), 7.4-7.5 (2H, m), 7.5-7.6 (1H, m), 7.6-7.7 (1H, m), 7.8-7.9 (1H, m), 8.03 (1H, bd, J=8.2), 8.0-8.1 (1H, m), 8.57 (1H, dd, J=1.5, 7.9).
CDCl3
[0426] 1.05 (3H, t, J=7.6), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.4-3.5 (2H, m), 7.4-7.5 (2H, m), 7.7-7.8 (1H, m), 7.8-7.9 (1H, m), 8.01 (1H, bd, J=8.5), 8.2-8.3 (1H, m), 8.39 (1H, brs), 8.55 (1H, dd, J=5, 7.9).
CDCl3
[0427] 1.04 (3H, t, J=7.4), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.4-3.5 (2H, m), 7.50 (2H, d, J=8.5), 7.6-7.7 (1H, m), 7.7-7.8 (1H, m), 8.01 (1H, bd, J=8.2), 8.33 (2H, d, J=8.5), 8.55 (1H, dd, J=0.9, 7.8).
CDCl3
[0428] 1.04 (3H, t, J=7.4), 1.5-1.6 (2H, m), 1.9-2.0 (2H, m), 3.4-3.5 (2H, m), 7.66 (2H, d, J=8.6), 7.6-7.7 (1H, m), 7.7-7.8 (1H, m), 8.01 (1H, bd, J=8.1), 8.26 (2H, d, J=8.6), 8.55 (1H, dd, J=1.1, 8.1).
CDCl3
[0429] 1.04 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.4-3.5 (2H, m), 7.33 (2H, d, J=8.0), 7.6-7.7 (1H, m), 7.7-7.8 (1H, m), 8.00 (1H, bd, J=8.2), 8.27 (2H, d, J=8.0), 8.56 (1H, dd, J=1.0, 7.9).
CDCl3
[0430] 1.04 (3H, t, J=7.3), 1.39 (9H, s), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.4-3.5 (2H, m), 7.55 (2H, d, J=8.5), 7.6-7.7 (1H, m), 7.7-7.8 (1H, m), 8.00 (1H, bd, J=8.2), 8.30 (2H, d, J=8.5), 857 (1H, dd, J=1.3, 7.9).
CDCl3
[0431] 1.05 (3H, t, J=7.5), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.4-3.5 (2H, m), 7.6-7.7 (1H, m), 7.77 (2H, d, J=7.9), 7.8-7.9 (1H, m), 8.01 (1H, bd, J=8.3), 8.49 (2H, d, J=7.9), 8.55 (1H, dd, J=1.2, 7.9).
CDCl3
[0432] 1.05 (3H, t, J=7.5), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.4-3.5 (2H, m), 7.3-7.4 (1H, m), 7.4-75 (2H, m), 7.6-7.7 (3H, m), 7.76 (2H, d, J=7.9), 7.7-7.8 (1H, m), 8.01 (1H, bd, J=8.3), 8.45 (2H, d, J=7.9), 8.58 (1H, dd, J=1.2, 7.9).
DMSO-d6
[0433] 0.99 (3H, t, J=7.4), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 6.96 (2H, d, J=8.6), 7.7-7.8 (1H, m), 7.8-7.9 (1H, m), 7.99 (1H, bd, J=8.2), 8.12 (2H, d, J=8.6), 8.43 (1H, bd, J=7.9).
CDCl3
[0434] 1.03 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.4-3.5 (2H, m), 3.98 (3H, s), 7.1-7.2 (2H, m), 7.4-7.5 (1H, m), 7.67 (1H, bt, J=7.9), 7.7-7.8 (1H, m), 8.01 (1H, bd, J=8.2), 8.06 (1H, dd, J=1.8, 7.6), 8.59 (1H, bd, J=7.9).
CDCl3
[0435] 1.04 (3H, t, J=7.4), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.4-3.5 (2H, m), 3.90 (3H, s), 7.04 (2H, d, J=8.9), 7.6-7.7 (1H, m), 7.7-7.8 (1H, m), 7.99 (1H, d, J=8.1), 8.32 (2H, bd, J=8.9), 856 (1H, dd, J=1.1, 7.9).
CDCl3
[0436] 1.04 (3H, t, J=7.3), 1.47 (3H, t, J=7.0), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.4-3.5 (2H, m), 4.13 (2H, q, J=7.0), 7.03 (2H, d, J=8.9), 7.6-7.7 (1H, m), 7.7-7.8 (1H, m), 7.99 (1H, bd, J=8.2), 8.31 (2H, d, J=8.9), 8.55 (1H, dd, J=1.0, 8.0).
CDCl3
[0437] 1.04 (3H, t, J=7.3), 1.08 (3H, t, J=7.6), 1.5-1.6 (2H, m), 1.8-1.9 (2H, m), 2.0-2.1 (2H, m); 3.4-3.5 (2H, m), 4.01 (2H, t, J=6.4), 7.03 (2H, d, J=8.8), 7.6-7.7 (1H, m), 7.7-7.8 (1H, m), 7.99 (1H, bd, J=8.2), 8.30 (2H, d, J=8.8), 8.55 (1H, dd, J=1.5, 7.9).
CDCl3
[0438] 1.05 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.4-3.5 (2H, m), 3.94 (3H, s), 4.04 (6H, s), 7.64 (2H, s), 7.6-7.7 (1H, m), 7.8-7.9 (1H, m), 8.01 (1H, bd, J=8.2), 8.57 (1H, dd, J=1.5, 7.9).
CDCl3
[0439] 1.04 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.06 (6H, s), 3.4-3.5 (2H, m), 6.81 (2H, d, J=9.1), 7.6-7.7 (1H, m), 7.7-7.8 (1H, m), 7.97 (1H, bd, J=8.2), 8.24 (2H, d, J=9.1), 855 (1H, dd, J=1.5, 7.9).
CDCl3
[0440] 1.05 (3H, t, J=7.4), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.4-3.5 (2H, m), 7.7-7.8 (1H, m), 7.8-7.9 (1H, m), 8.04 (1H, bd, J=8.1), 8.38 (2H, d, J=9.0), 8.5-8.6 (1H, m), 8.58 (2H, d, J=9.0).
CDCl3
[0441] 1.05 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.4-3.5 (2H, m), 7.46 (1H, dd, J=5.0, 7.9), 7.6-7.7 (1H, m), 7.8-7.9 (1H, m), 8.02 (1H, bd, J=8.2), 8.56 (1H, dd, J=1.5, 7.9), 8.64 (1H, dt, J=7.9, 2.1), 8.74 (1H, dd, J=2.1, 5.0), 9.59 (1H, bd, J=2.1).
CDCl3
[0442] 1.03 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.4-3.5 (2H, m), 6.61 (1H, dd, J=1.8, 3.2), 7.30 (1H, dd, J=0.6, 3.2), 7.66 (1H, dd, J=0.6, 1.8), 7.6-7.7 (1H, m), 7.8-7.9 (1H, m), 8.01 (1H, bd, J=8.5), 8.56 (1H, dd, J=1.5, 7.9).
CDCl3
[0443] 1.04 (3H, t, J=7.6), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.3-3.4 (2H, m), 7.19 (1H, dd, J=3.8, 53), 7.49 (1H, dd, J=1.2, 5.3), 7.6-7.7 (1H, m), 7.7-7.8 (1H, m), 7.9-8.0 (2H, m), 8.55 (1H, dd, J=1.5, 7.9).
CDCl3
[0444] 1.05 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.4-3.5 (2H, m), 7.40 (1H, bt, J=8.2), 75-7.6 (3H, m), 7.75 (1H, dt, J=5.6, 8.2), 7.82 (1H, bd, J=8.2), 8.4-8.5 (2H, m).
CDCl3
[0445] 1.04 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.4-3.5 (2H, m), 7.5-7.6 (3H, m), 7.68 (1H, bt, J=7.9), 7.72 (1H, dd, J=1.8, 7.9), 7.93 (1H, dd, J=1.8, 7.9), 8.4-8.5 (2H, m).
CDCl3
[0446] 1.04 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.4-3.5 (2H, m), 7.5-7.6 (3H, m), 7.73 (1H, dd, J=2.6, 8.8), 7.93 (1H, d, J=8.8), 8.3-8.4 (2H, m), 8.55 (1H, d, J=2.6).
CDCl3
[0447] 1.04 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.4-3.5 (2H, m), 7.5-7.6 (3H, m), 7.64 (1H, dd, J=2.0, 8.8), 8.01 (1H, d, J=2.0), 8.3-8.4 (2H, m), 8.49 (1H, d, J=8.8).
CDCl3
[0448] 1.04 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.3-3.4 (2H, m), 7.5-7.6 (3H, m), 7.8-7.9 (2H, m), 8.3-8.4 (2H, m), 8.7-8.8 (1H, m).
CDCl3
[0449] 1.04 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.3-3.4 (2H, m), 4.06 (3H, s), 4.12 (3H, s), 7.41 (1H, s), 7.5-7.6 (3H, m), 7.86 (1H, s), 8.3-8.4 (2H, m).
CDCl3
[0450] 1.04 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.18 (3H, s), 3.4-3.5 (2H, m), 7.4-7.6 (4H, m), 7.66 (1H, bt, J=7.9), 7.84 (1H, bd, J=7.9), 8.4-8.5 (2H, m).
CDCl3
[0451] 1.04 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 2.58 (3H, s), 3.4-3.5 (2H, m), 7.5-7.6 (4H, m), 7.81 (1H, bs), 8.3-8.4 (2H, m), 8.44 (1H, d, J=8.2).
DMSO-d6
[0452] 0.97 (3H, t, J=7.5), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 7.5-7.6 (2H, m), 7.6-7.7 (1H, m), 8.08 (1H, dd, J=2.5, 7.1), 8.57 (1H, bs).
DMSO-d6
[0453] 0.99 (3H, t, J=7.5), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 7.5-7.6 (2H, m), 8.1-8.2 (2H, m), 8.52 (1H, bs).
DMSO-d6
[0454] 0.98 (3H, t, J=7.5), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 3.88 (3H, s), 7.11 (1H, bt, J=7.5), 7.22 (1H, bd, J=8.7), 7.52 (1H, m), 7.93 (1H, dd, J=1.7, 75), 8.53 (1H, bs).
DMSO-d6
[0455] 0.99 (3H, t, J=7.5), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 3.87 (3H, s), 7.11 (1H, dd, J=2.5, 7.9), 7.48 (1H, bt, J=7.9), 7.7-7.8 (1H, m), 7.84 (1H, bd, J=7.9), 8.56 (1H, bs).
DMSO-d6
[0456] 0.98 (3H, t, J=7.5), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 3.85 (3H, s), 7.10 (2H, d, J=9.1), 8.17 (2H, d, J=9.1), 8.52 (1H, bs).
DMSO-d6
[0457] 0.98 (3H, t, J=7.5), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 2.55 (3H, s), 3.3-3.4 (2H, m), 7.41 (2H, d, J=8.7), 8.15 (2H, d, J=8.7), 8.53 (1H, bs).
CDCl3
[0458] 1.04 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.4-3.5 (2H, m), 3.95 (3H, s), 7.05 (1H, dd, J=2.6, 7.9), 7.44 (1H, t, J=7.9), 7.6-7.7 (1H, m), 7.8-7.9 (1H, m), 7.9-8.0 (1H, m), 8.0-8.1 (2H, m), 8.57 (1H, dd, J=1.5, 8.2).
CDCl3
[0459] 1.04 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 2.56 (3H, s), 3.4-3.5 (2H, m), 7.37 (2H, d, J=8.5), 7.6-7.7 (1H, m), 7.7-7.8 (1H, m), 8.00 (1H, bd, J=8.2), 8.29 (2H, d, J=8.5), 856 (1H, dd, J=1.5, 7.9).
DMSO-d6
[0460] 7.5-7.6 (3H, m), 7.6-7.7 (3H, m), 8.2-8.3 (2H, m), 8.4-8.5 (2H, m), 8.65 (1H, bs).
DMSO-d6
[0461] 1.07 (3H, t, J=7.5), 1.9-2.0 (2H, m), 2.40 (3H, s), 3.3-3.4 (2H, m), 7.37 (2H, d, J=8.3), 8.14 (2H, d, J=8.3), 8.54 (1H, bs).
CDCl3
[0462] 1.05 (3H, t, J=7.5), 1.30 (3H, t, J=7.5), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 2.74 (2H, q, J=7.5), 3.3-3.4 (2H, m), 7.35 (2H, d, J=8.3), 8.26 (2H, d, J=8.3), 8.47 (1H, s).
CDCl3
[0463] 0.98 (3H, t, J=7.5), 1.05 (3H, t, J=7.5), 1.5-1.6 (2H, m), 1.6-1.7 (2H, m), 2.0-2.1 (2H, m), 2.6-2.7 (2H, m), 3.4-3.5 (2H, m), 7.33 (2H, d, J=8.3), 8.25 (2H, d, J=8.3), 8.47 (1H, s).
DMSO-d6
[0464] 1.45 (3H, t, J=7.5), 3.36 (2H, q, J=7.5), 3.85 (3H, s), 7.10 (2H, d, J=8.7), 8.18 (2H, d, J=8.7), 8.53 (1H, bs).
DMSO-d6
[0465] 1.44 (3H, t, J=7.5), 3.35 (2H, q, J=7.5), 7.61 (2H, d, J=8.3), 8.22 (2H, d, J=8.3), 8.54 (1H, bs).
DMSO-d6
[0466] 1.44 (3H, t, J=7.5), 2.39 (3H, s), 3.36 (2H, q, J=7.5), 7.35 (2H, d, J=8.3), 8.12 (2H, d, J=8.3), 8.53 (1H, bs).
CDCl3
[0467] 1.58 (3H, t, J=7.6), 3.45 (2H, q, J=7.6), 7.65 (2H, d, J=8.5), 7.6-7.7 (1H, m), 7.8-7.9 (1H, m), 8.02 (1H, bd, J=8.2), 8.25 (2H, d, J=8.5), 8.5-8.6 (1H, m).
CDCl3
[0468] 1.59 (3H, t, J=7.3), 3.45 (2H, q, J=7.3), 7.21 (2H, t, J=8.8), 7.6-7.7 (1H, m), 7.8-7.9 (1H, m), 8.02 (1H, bd, J=8.2), 8.38 (2H, dd, J=5.6, 8.8), 8.56 (1H, dd, J=1.5, 7.9).
CDCl3
[0469] 1.58 (3H, t, J=7.3), 3.44 (2H, q, J=7.3), 7.49 (2H, d, J=8.5), 7.68 (1H, bt, J=7.3), 7.8-7.9 (1H, m), 8.02 (1H, bd, J=8.2), 8.32 (2H, d, J=8.5), 8.5-8.6 (1H, m).
CDCl3
[0470] 1.59 (3H, t, J=7.6), 2.44 (3H, s), 3.46 (2H, q, J=7.6), 7.33 (2H, d, J=8.5), 7.6-7.7 (1H, m), 7.8-7.9 (1H, m), 8.01 (1H, bd, J=8.2), 8.27 (2H, d, J=8.5), 8.57 (1H, dd, J=1.5, 7.9).
DMSO-d6
[0471] 1.48 (3H, t, J=7.5), 3.36 (2H, q, J=7.5), 6.95 (2H, d, J=8.7), 7.7-7.8 (1H, m), 7.8-7.9 (1H, m), 8.00 (1H, bd, J=8.3), 8.12 (2H, d, J=8.7), 8.44 (1H, dd, J=1.2, 7.9).
CDCl3
[0472] 1.58 (3H, t, J=7.5), 3.44 (2H, q, J=7.5), 3.89 (3H, s), 7.03 (2H, d, J=8.7), 7.6-7.7 (1H, m), 7.7-7.8 (1H, m), 8.00 (1H, bd, J=8.3), 8.31 (2H, d, J=8.7), 8.55 (1H, dd, J=1.3, 75).
CDCl3
[0473] 1.47 (3H, t, J=7.0), 1.58 (3H, t, J=7.6), 3.45 (2H, q, J=7.6), 4.13 (2H, q, J=7.0), 7.03 (2H, d, J=8.8), 7.6-7.7 (1H, m), 7.7-7.8 (1H, m), 8.01 (1H, bd, J=7.9), 8.30 (2H, d, J=8.8), 8.56 (1H, dd, J=1.2, 8.2).
CDCl3
[0474] 1.15 (3H, t, J=7.3), 2.0-2.1 (2H, m), 3.3-3.4 (2H, m), 7.5-7.6 (3H, m), 7.74 (1H, dd, J=2.3, 8.8), 7.94 (1H, d, J=8.8), 8.3-8.4 (2H, m), 8.55 (1H, d, J=2.3).
CDCl3
[0475] 1.04 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.3-3.4 (2H, m), 7.21 (2H, t, J=8.8), 7.73 (1H, dd, J=2.3, 8.8), 7.93 (1H, d, J=8.8), 8.36 (2H, dd, J=5.6, 8.8), 8.52 (1H, d, J=2.3).
CDCl3
[0476] 1.04 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.3-3.4 (2H, m), 7.49 (2H, d, J=8.8), 7.73 (1H, dd, J=2.3, 8.8), 7.93 (1H, d, J=8.8), 8.29 (2H, d, J=8.8), 8.51 (1H, d, J=2.3).
CDCl3
[0477] 1.04 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.3-3.4 (2H, m), 7.65 (2H, d, J=8.5), 7.73 (1H, dd, J=2.3, 8.8), 7.93 (1H, d, J=8.8), 8.23 (2H, d, J=8.5), 8.51 (1H, d, J=2.3).
CDCl3
[0478] 1.04 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 2.45 (3H, s), 3.4-3.5 (2H, m), 7.33 (2H, d, J=8.2), 7.72 (1H, dd, J=2.3, 8.8), 7.92 (1H, d, J=8.8), 8.25 (2H, d, J=8.2), 8.54 (1H, d, J=2.3).
CDCl3
[0479] 1.04 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.3-3.4 (2H, m), 3.90 (3H, s), 7.04 (2H, d, J=8.8), 7.72 (1H, dd, J=2.3, 8.8), 7.92 (1H, d, J=8.8), 8.30 (2H, d, J=8.8), 8.53 (1H, d, J=2.3).
CDCl3
[0480] 1.15 (3H, t, J=7.3), 2.0-2.1 (2H, m), 3.3-3.4 (2H, m), 7.5-7.6 (3H, m), 7.64 (1H, dd, J=2.0, 85), 8.02 (1H, d, J=2.0), 8.3-8.4 (2H, m), 8.50 (1H, d, J=8.85).
CDCl3
[0481] 1.04 (3H, t, J=7.6), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.4-3.5 (2H, m), 7.21 (2H, t, J=8.8), 7.64 (1H, dd, J=2.1, 85), 8.02 (1H, d, J=2.1), 8.36 (2H, dd, J=5.3, 8.8), 8.48 (1H, d, J=8.5).
CDCl3
[0482] 1.04 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.3-3.4 (2H, m), 7.49 (2H, d, J=8.5), 7.63 (1H, dd, J=2.0, 85), 8.00 (1H, d, J=2.0), 8.29 (2H, d, J=8.5), 8.45 (1H, d, J=8.5).
CDCl3
[0483] 1.04 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.3-3.4 (2H, m), 7.6-7.7 (1H, m), 7.65 (2H, d, J=8.2), 8.02 (1H, d, J=1.8), 8.24 (2H, d, J=8.2), 8.47 (1H, d, J=8.8).
CDCl3
[0484] 1.04 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 2.45 (3H, s), 3.4-3.5 (2H, m), 7.33 (2H, d, J=8.2), 7.63 (1H, dd, J=1.8, 85), 8.00 (1H, d, J=1.8), 8.25 (2H, d, J=8.2), 8.49 (1H, d, J=8.5).
CDCl3
[0485] 1.04 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.3-3.4 (2H, m), 3.90 (3H, s), 7.04 (2H, d, J=8.8), 7.62 (1H, dd, J=2.0, 85), 8.00 (1H, d, J=2.0), 8.29 (2H, d, J=8.8), 8.47 (1H, d, J=8.5).
CDCl3
[0486] 1.06 (3H, t, J=7.3), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.4-3.5 (2H, m), 7.5-7.6 (3H, m), 8.14 (1H, d, J=9.1), 8.3-8.4 (214, m), 8.59 (1H, dd, J=2.6, 9.1), 9.47 (1H, d, J=2.6).
CDCl3
[0487] 1.57 (3H, t, J=7.6), 3.43 (2H, q, J=7.6), 7.49 (2H, d, J=8.2), 7.74 (1H, dd, J=2.3, 8.8), 7.95 (1H, d, J=8.8), 8.30 (2H, d, J=8.2), 8.52 (1H, d, J=2.3).
DMSO-d6
[0488] 0.92 (3H, t, J=7.1), 1.4-1.5 (4H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 7.5-7.6 (3H, m), 8.2-8.3 (2H, m), 8.56 (1H, bs).
CDCl3
[0489] 0.92 (3H, t, J=7.1), 1.3-1.5 (4H, m), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.4-3.5 (2H, m), 7.5-7.6 (3H, m), 8.3-8.4 (2H, m), 8.46 (1H, s).
DMSO-d6
[0490] 2.2-2.3 (2H, m), 2.58 (2H, t, J=7.5), 3.41 (2H, t, J=7.5), 3.58 (3H, s), 7.5-7.6 (3H, m), 8.2-8.3 (2H, m), 8.57 (1H, bs).
DMSO-d6
[0491] 2.2-2.3 (2H, m), 2.57 (2H, t, J=7.5), 3.38 (2H, t, J=7.5), 3.57 (3H, s), 3.85 (3H, s), 7.11 (2H, d, J=9.1), 8.18 (2H, d, J=9.1), 8.53 (1H, bs).
DMSO-d6
[0492] 2.2-2.3 (2H, m), 2.57 (2H, t, J=7.5), 3.39 (2H, t, J=7.5), 3.57 (3H, s), 7.63 (2H, d, J=8.3), 8.25 (2H, d, J=8.3), 8.55 (1H, bs).
DMSO-d6
[0493] 2.2-2.3 (2H, m), 2.40 (3H, s), 2.57 (2H, t, J=7.5), 3.39 (2H, t, J=7.5), 3.57 (3H, s), 7.37 (2H, d, J=7.9), 8.14 (2H, d, J=7.9), 8.54 (1H, bs).
CDCl3
[0494] 0.96 (3H, t, J=7.1), 1.4-1.6 (4H, m), 2.0-2.1 (2H, m), 3.4-3.5 (2H, m), 7.5-7.6 (3H, m), 7.6-7.7 (1H, m), 7.7-7.8 (1H, m), 8.00 (1H, bd, J=8.3), 8.3-8.4 (2H, m), 8.57 (1H, dd, J=0.8, 7.9).
CDCl3
[0495] 0.92 (3H, t, J=7.0), 1.3-1.5 (4H, m), 1.5-1.6 (2H, m), 2.0-2.1 (2H, m), 3.4-3.5 (2H, m), 7.5-7.6 (3H, m), 7.6-7.7 (1H, m), 7.7-7.8 (1H, m), 8.00 (1H, bd, J=8.2), 8.3-8.4 (2H, m), 8.57 (1H, dd, J=1.5, 8.2).
CDCl3
[0496] 0.96 (3H, t, J=7.3), 1.4-1.6 (4H, m), 2.0-2.1 (2H, m), 3.3-3.4 (2H, m), 7.21 (2H, t, J=8.8), 7.6-7.7 (1H, m), 7.7-7.8 (1H, m), 8.00 (1H, bd, J=8.2), 8.37 (2H, dd, J=5.6, 8.8), 8.54 (1H, dd, J=1.5, 8.2).
CDCl3
[0497] 2.4-2.5 (2H, m), 2.60 (2H, t, J=7.3), 3.50 (2H, t, J=7.3), 3.67 (3H, s), 7.5-7.6 (3H, m), 7.6-7.7 (1H, m), 7.8-7.9 (1H, m), 8.02 (1H, bd, J=8.2), 8.3-8.4 (2H, m), 8.58 (1H, dd, J=1.5, 7.9).
CDCl3
[0498] 2.4-2.5 (2H, m), 2.60 (2H, t, J=7.6), 3.48 (2H, t, J=7.6), 3.67 (3H, s), 7.65 (2H, d, J=8.2), 7.6-7.7 (1H, m), 7.8-7.9 (1H, m), 8.00 (1H, bd, J=8.2), 8.24 (2H, d, J=8.2), 8.54 (1H, dd, J=1.5, 8.2).
CDCl3
[0499] 2.4-2.5 (2H, m), 2.60 (2H, t, J=7.3), 3.48 (2H, t, J=7.3), 3.67 (3H, s), 7.21 (2H, t, J=9.1), 7.7-7.8 (1H, m), 7.8-7.9 (1H, m), 8.00 (1H, bd, J=8.5), 8.37 (2H, dd, J=5.6, 9.1), 8.5-8.6 (1H, m).
CDCl3
[0500] 2.4-2.5 (2H, m), 2.61 (2H, t, J=7.3), 3.48 (2H, t, J=7.6), 3.67 (3H, s), 7.49 (2H, d, J=8.2), 7.69 (1H, bt, J=7.3), 7.8-7.9 (1H, m), 8.01 (1H, bd, J=8.2), 8.31 (2H, d, J=8.2), 8.5-8.6 (1H, m).
CDCl3
[0501] 2.4-2.5 (2H, m), 2.44 (3H, s), 2.60 (2H, t, J=7.6), 3.49 (2H, t, J=7.3), 3.67 (3H, s), 7.32 (2H, d, J=8.2), 7.6-7.7 (1H, m), 7.7-7.8 (1H, m), 8.00 (1H, bd, J=8.2), 8.26 (2H, d, J=8.2), 8.56 (1H, dd, J=0.9, 7.9).
CDCl3
[0502] 0.96 (3H, t, J=7.3), 1.4-1.6 (4H, m), 2.0-2.1 (2H, m), 2.45 (3H, s), 3.4-3.5 (2H, m), 7.33 (2H, d, J=8.2), 7.6-7.7 (1H, m), 7.7-7.8 (1H, m), 8.00 (1H, bd, J=8.2), 8.27 (2H, d, J=8.2), 856 (1H, dd, J=1.5, 7.9).
CDCl3
[0503] 0.96 (3H, t, J=7.3), 1.4-1.6 (4H, m), 2.0-2.1 (2H, m), 3.3-3.4 (2H, m), 7.65 (2H, d, J=8.5), 7.6-7.7 (1H, m), 7.8-7.9 (1H, m), 8.01 (1H, bd, J=8.5), 8.26 (2H, d, J=8.5), 8.54 (1H, dd, J=1.5, 8.2).
CDCl3
[0504] 0.96 (3H, t, J=7.3), 1.4-1.6 (4H, m), 2.0-2.1 (2H, m), 3.3-3.4 (2H, m), 7.49 (2H, d, J=8.2), 7.6-7.7 (1H, m), 7.8-7.9 (1H, m), 8.01 (1H, bd, J=8.5), 8.32 (2H, d, J=8.2), 8.54 (1H, dd, J=1.5, 7.9).
CDCl3
[0505] 2.3-2.5 (2H, m), 2.60 (2H, t, J=7.3), 3.46 (2H, t, J=7.3), 3.67 (3H, s), 7.49 (2H, d, J=8.5), 7.74 (1H, dd, J=2.3, 8.8), 7.93 (1H, d, J=8.8), 8.29 (2H, d, J=8.5), 8.52 (1H, d, J=2.3).
CDCl3
[0506] 0.96 (3H, t, J=7.0), 1.4-1.6 (4H, m), 2.0-2.1 (2H, m), 3.3-3.4 (2H, m), 3.90 (3H, s), 7.04 (2H, d, J=9.1), 7.6-7.7 (1H, m), 7.7-7.8 (1H, m), 7.99 (1H, bd, J=8.5), 8.32 (2H, d, J=9.1), 8.55 (1H, dd, J=0.9, 7.9).
CDCl3
[0507] 0.96 (3H, t, J=7.3), 1.47 (3H, t, J=7.0), 1.4-1.6 (4H, m), 2.0-2.1 (2H, m), 3.3-3.4 (2H, m), 4.12 (2H, q, J=7.0), 7.02 (2H, d, J=8.5), 7.6-7.7 (1H, m), 7.7-7.8 (1H, m), 7.99 (1H, bd, J=8.2), 8.30 (2H, d, J=8.5), 8.54 (1H, bd, J=7.9).
CDCl3
[0508] 0.95 (3H, t, J=7.1), 0.96 (3H, t, J=7.1), 1.4-1.6 (8H, m), 1.7-1.8 (2H, m), 2.0-2.1 (2H, m), 2.5-2.6 (2H, m), 3.4-3.5 (2H, m), 7.26 (2H, d, J=8.7), 7.6-7.7 (1H, m), 7.8-7.9 (1H, m), 8.01 (1H, bd, J=7.9), 8.41 (2H, d, J=8.7), 8.56 (1H, dd, J=0.8, 7.9).
DMSO-d6
[0509] 0.99 (3H, t, J=7.3), 1.4-1.6 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 4.10 (3H, s), 7.40 (2H, t, J=8.8), 8.29 (2H, dd, J=5.6, 8.8), 8.45 (1H, s).
DMSO-d6
[0510] 0.98 (3H, t, J=7.3), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.2-3.3 (2H, m), 4.17 (3H, s), 7.39 (2H, t, J=8.8), 8.25 (2H, dd, J=5.6, 8.8), 8.82 (1H, s).
DMSO-d6
[0511] 0.99 (3H, t, J=7.3), 1.5-1.6 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 4.11 (3H, s), 7.5-7.6 (3H, m), 8.2-8.3 (2H, m), 8.47 (1H, s).
DMSO-d6
[0512] 0.98 (3H, t, J=7.3), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 4.17 (3H, s), 7.5-7.6 (3H, m), 8.2-8.3 (2H, m), 8.84 (1H, s).
DMSO-d6
[0513] 0.86 (3H, t, J=7.6), 0.99 (3H, t, J=7.3), 1.4-1.5 (2H, m), 1.9-2.0 (4H, m), 3.3-3.4 (2H, m), 4.45 (2H, t, J=7.0), 7.5-7.6 (3H, m), 8.2-8.3 (2H, m), 8.48 (1H, s).
DMSO-d6
[0514] 0.88 (3H, t, J=7.3), 0.99 (3H, t, J=7.3), 1.4-1.5 (2H, m), 1.9-2.0 (4H, m), 3.3-3.4 (2H, m), 4.39 (2H, t, J=7.0), 7.5-7.6 (3H, m), 8.2-8.3 (2H, m), 8.90 (1H, s).
DMSO-d6
[0515] 0.99 (3H, t, J=7.6), 1.49 (3H, t, J=7.3), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 4.52 (2H, q, J=7.3), 7.5-7.6 (3H, m), 8.2-8.3 (2H, m), 8.48 (1H, s).
DMSO-d6
[0516] 0.98 (3H, t, J=7.3), 1.4-1.5 (2H, m), 1.53 (3H, t, J=7.3), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 4.46 (2H, q, J=7.3), 7.5-7.6 (3H, m), 8.2-8.3 (2H, m), 8.91 (1H, s).
DMSO-d6
[0517] 0.99 (3H, t, J=7.3), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 5.71 (2H, s), 7.2-7.4 (5H, m), 7.5-7.6 (3H, m), 8.2-8.3 (2H, m), 8.51 (1H, s).
DMSO-d6
[0518] 0.97 (3H, t, J=7.3), 1.4-1.5 (2H, m), 1.8-1.9 (2H, m), 3.2-3.3 (2H, m), 5.65 (2H, s), 7.3-7.4 (5H, m), 7.5-7.6 (3H, m), 8.2-8.3 (2H, m), 9.05 (1H, s).
DMSO-d6
[0519] 0.99 (3H, t, J=7.6), 1.4-1.6 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 4.08 (3H, s), 7.60 (2H, d, J=8.5), 8.20 (2H, d, J=8.5), 8.42 (1H, s).
DMSO-d6
[0520] 0.98 (3H, t, J=7.3), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.2-3.3 (2H, m), 4.17 (3H, s), 7.62 (2H, d, J=8.5), 8.21 (2H, d, J=8.5), 8.83 (1H, s).
DMSO-d6
[0521] 0.99 (3H, t, J=7.3), 1.4-1.6 (2H, m), 1.9-2.0 (2H, m), 2.40 (3H, s), 3.3-3.4 (2H, m), 4.10 (3H, s), 7.38 (2H, d, J=7.9), 8.15 (2H, d, J=7.9), 8.45 (1H, s).
DMSO-d6
[0522] 0.97 (3H, t, J=7.3), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 2.39 (3H, s), 3.2-3.3 (2H, m), 4.16 (3H, s), 7.36 (2H, d, J=7.9), 8.11 (2H, d, J=7.9), 8.81 (1H, s).
DMSO-d6
[0523] 0.86 (3H, t, J=7.5), 0.99 (3H, t, J=7.5), 1.4-1.6 (2H, m), 1.9-2.0 (4H, m), 2.40 (3H, s), 3.3-3.4 (2H, m), 4.45 (2H, t, J=7.1), 7.38 (2H, d, J=7.9), 8.15 (2H, d, J=7.9), 8.46 (1H, s).
DMSO-d6
[0524] 0.88 (3H, t, J=7.5), 0.98 (3H, t, J=7.5), 1.4-1.5 (2H, m), 1.8-2.0 (4H, m), 2.39 (3H, s), 3.2-3.3 (2H, m), 4.38 (2H, t, J=7.1), 7.36 (2H, d, J=7.9), 8.11 (2H, d, J=7.9), 8.87 (1H, s).
DMSO-d6
[0525] 0.86 (3H, t, J=7.5), 0.99 (3H, t, J=7.5), 1.4-1.6 (2H, m), 1.9-2.0 (4H, m), 3.3-3.4 (2H, m), 4.45 (2H, t, J=7.1), 7.40 (2H, t, J=8.7), 8.30 (2H, dd, J=5.4, 8.7), 8.47 (1H, s).
DMSO-d6
[0526] 0.88 (3H, t, J=7.5), 0.98 (3H, t, J=7.5), 1.4-1.5 (2H, m), 1.9-2.0 (4H, m), 3.2-3.3 (2H, m), 439 (2H, t, J=7.1), 7.39 (2H, t, J=8.7), 8.26 (2H, dd, J=5.4, 8.7), 8.89 (1H, s).
DMSO-d6
[0527] 0.86 (3H, t, J=7.5), 0.98 (3H, t, J=7.5), 1.4-1.6 (2H, m), 1.9-2.0 (4H, m), 3.3-3.4 (2H, m), 4.45 (2H, t, J=7.1), 7.61 (2H, d, J=8.7), 8.25 (2H, d, J=8.7), 8.47 (1H, s).
DMSO-d6
[0528] 0.88 (3H, t, J=7.5), 0.98 (3H, t, J=7.5), 1.4-1.5 (2H, m), 1.9-2.0 (4H, m), 3.2-3.3 (2H, m), 439 (2H, t, J=7.1), 7.63 (2H, d, J=8.7), 8.22 (2H, d, J=8.7), 8.90 (1H, s).
DMSO-d6
[0529] 0.97 (3H, t, J=7.3), 1.22 (3H, t, J=7.0), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 4.19 (2H, q, J=7.0), 5.41 (2H, s), 7.5-7.6 (3H, m), 8.2-8.3 (2H, m), 8.56 (1H, s).
DMSO-d6
[0530] 0.99 (3H, t, J=7.3), 1.25 (3H, t, J=7.0), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 4.21 (2H, q, J=7.0), 5.43 (2H, s), 7.5-7.6 (3H, m), 8.2-8.3 (2H, m), 8.89 (1H, s).
DMSO-d6
[0531] 0.97 (3H, t, J=7.3), 1.22 (3H, t, J=7.0), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 4.19 (2H, q, J=7.0), 5.41 (2H, s), 7.41 (2H, t, J=8.8), 8.30 (2H, dd, J=5.6, 8.8), 8.55 (1H, s).
DMSO-d6
[0532] 0.98 (3H, t, J=7.3), 1.24 (3H, t, J=7.0), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.2-3.3 (2H, m), 4.21 (2H, q, J=7.0), 5.43 (2H, s), 7.40 (2H, t, J=8.8), 8.27 (2H, dd, J=5.6, 8.8), 8.88 (1H, s).
DMSO-d6
[0533] 0.99 (3H, t, J=7.6), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 3.91 (2H, bq, J=5.6), 4.52 (2H, bt, J=5.6), 4.93 (1H, bt, J=5.6), 7.5-7.6 (3H, m), 8.2-8.3 (2H, m), 8.46 (1H, s).
DMSO-d6
[0534] 0.98 (3H, t, J=7.3), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 3.90 (2H, bq, J=5.3), 4.47 (2H, bt, J=5.3), 5.03 (1H, bt, J=5.3), 7.5-7.6 (3H, m), 8.2-8.3 (2H, m), 8.83 (1H, s).
DMSO-d6
[0535] 0.99 (3H, t, J=7.3), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 3.91 (2H, bq, J=5.6), 4.51 (2H, bt, J=5.6), 4.92 (1H, bt, J=5.6), 7.38 (2H, t, J=8.8), 8.26 (2H, dd, J=5.6, 8.8), 8.45 (1H, s).
DMSO-d6
[0536] 0.98 (3H, t, J=7.3), 1.4-1.5 (2H, m), 1.8-2.0 (2H, m), 3.2-3.3 (2H, m), 3.90 (2H, bq, J=5.3), 4.46 (2H, bt, J=5.3), 5.03 (1H, bt, J=5.3), 7.39 (2H, t, J=8.8), 8.25 (2H, dd, J=5.6, 8.8), 8.82 (1H, s).
DMSO-d6
[0537] 0.99 (3H, t, J=7.3), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 2.40 (3H, s), 3.3-3.4 (2H, m), 3.91 (2H, bq, J=5.9), 4.52 (2H, bt, J=5.9), 4.90 (1H, bt, J=5.9), 7.37 (2H, d, J=8.2), 8.14 (2H, d, J=8.2), 8.46 (1H, s).
DMSO-d6
[0538] 0.98 (3H, t, J=7.3), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 2.39 (3H, s), 3.2-3.3 (2H, m), 3.90 (2H, bt, J=5.6), 4.46 (2H, bt, J=5.6), 7.36 (2H, d, J=8.2), 8.11 (2H, d, J=8.2), 8.81 (1H, s).
DMSO-d6
[0539] 0.99 (3H, t, J=7.5), 1.4-1.6 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 3.91 (2H, bq, J=5.8), 4.53 (2H, bt, J=5.8), 4.90 (1H, bt, J=5.8), 7.63 (2H, d, J=8.3), 8.25 (2H, d, J=8.3), 8.47 (1H, s).
DMSO-d6
[0540] 0.98 (3H, t, J=7.5), 1.4-1.5 (2H, m), 1.8-2.0 (2H, m), 3.2-3.3 (2H, m), 3.9-4.0 (2H, m), 4.46 (2H, bt, J=5.4), 5.0-5.1 (1H, m), 7.63 (2H, d, J=8.7), 8.23 (2H, d, J=8.7), 8.83 (1H, s).
DMSO-d6
[0541] 0.99 (3H, t, J=7.5), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 3.85 (3H, s), 3.91 (2H, bq, J=5.8), 4.52 (2H, bt, J=5.8), 4.90 (1H, bt, J=5.8), 7.11 (2H, d, J=8.7), 8.18 (2H, d, J=8.7), 8.45 (1H, s).
DMSO-d6
[0542] 0.98 (3H, t, J=7.5), 1.4-1.5 (2H, m), 1.8-2.0 (2H, m), 3.2-3.3 (2H, m), 3.85 (3H, s), 3.8-3.9 (2H, m), 4.46 (2H, bt, J=5.4), 5.0-5.1 (1H, m), 7.10 (2H, d, J=9.1), 8.15 (2H, d, J=9.1), 8.80 (1H, s).
DMSO-d6
[0543] 0.98 (3H, t, J=7.5), 1.4-1.5 (2H, m), 1.53 (3H, t, J=7.5), 1.9-2.0 (2H, m), 3.2-3.3 (2H, m), 3.85 (3H, s), 4.45 (2H, q, J=7.5), 7.11 (2H, d, J=8.7), 8.16 (2H, d, J=8.7), 8.88 (1H, s).
DMSO-d6
[0544] 0.98 (3H, t, J=7.5), 1.4-1.5 (2H, m), 1.53 (3H, t, J=7.5), 1.9-2.0 (2H, m), 2.40 (3H, s), 3.2-3.3 (2H, m), 4.46 (2H, q, J=7.5), 7.37 (2H, d, J=7.9), 8.12 (2H, d, J=7.9), 8.89 (1H, s).
DMSO-d6
[0545] 0.98 (3H, t, J=7.5), 1.4-1.5 (2H, m), 1.53 (3H, t, J=7.5), 1.9-2.0 (2H, m), 3.2-3.3 (2H, m), 4.46 (2H, q, J=7.5), 7.40 (2H, t, J=8.7), 8.26 (2H, dd, J=5.4, 8.7), 8.90 (1H, s).
DMSO-d6
[0546] 0.98 (3H, t, J=7.5), 1.4-1.5 (2H, m), 1.53 (3H, t, J=7.5), 1.9-2.0 (2H, m), 3.2-3.3 (2H, m), 4.46 (2H, q, J=7.5), 7.63 (2H, d, J=8.7), 8.23 (2H, d, J=8.7), 8.90 (1H, s).
DMSO-d6
[0547] 0.87 (3H, t, J=7.5), 0.98 (3H, t, J=7.5), 1.4-1.5 (2H, m), 1.8-2.0 (4H, m), 3.2-3.3 (2H, m), 3.85 (3H, s), 4.38 (2H, t, J=7.0), 7.11 (2H, d, J=8.7), 8.16 (2H, d, J=8.7), 8.88 (1H, s).
DMSO-d6
[0548] 2.1-2.3 (2H, m), 2.48 (2H, t, J=7.5), 3.40 (2H, t, J=7.5), 7.5-7.6 (3H, m), 8.2-8.3 (2H, m), 8.56 (1H, bs).
DMSO-d6
[0549] 2.1-2.2 (2H, m), 2.47 (2H, t, J=7.5), 3.38 (2H, t, J=7.5), 3.85 (3H, s), 7.11 (2H, d, J=8.7), 8.19 (2H, d, J=8.7), 8.53 (1H, bs).
DMSO-d6
[0550] 2.1-2.2 (2H, m), 2.47 (2H, t, J=7.5), 3.39 (2H, t, J=7.5), 7.63 (2H, d, J=8.3), 8.26 (2H, d, J=8.3), 8.56 (1H, bs).
DMSO-d6
[0551] 2.1-2.2 (2H, m), 2.40 (3H, s), 2.47 (2H, t, J=7.5), 3.39 (2H, t, J=7.5), 7.37 (2H, d, J=7.9), 8.15 (2H, d, J=7.9), 8.54 (1H, bs).
DMSO-d6
[0552] 0.98 (3H, t, J=7.5), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 5.29 (2H, s), 7.5-7.6 (3H, m), 8.2-8.3 (2H, m), 8.52 (1H, s).
DMSO-d6
[0553] 0.97 (3H, t, J=7.5), 1.4-1.5 (2H, m), 1.9-2.0 (2H, m), 3.2-3.3 (2H, m), 5.29 (2H, s), 7.5-7.6 (3H, m), 8.2-8.3 (2H, m), 8.84 (1H, s).
DMSO-d6
[0554] 2.2-2.3 (2H, m), 2.50 (2H, t, J=7.5), 3.40 (2H, t, J=7.5), 7.5-7.6 (3H, m), 7.77 (1H, bt, J=7.9), 7.91 (1H, bt, J=7.9), 8.01 (1H, bd, J=7.9), 8.2-8.3 (2H, m), 8.46 (1H, bd, J=7.9).
DMSO-d6
[0555] 2.2-2.3 (2H, m), 2.49 (2H, t, J=7.5), 3.39 (2H, t, J=7.5), 7.7-7.8 (1H, m), 7.77 (2H, d, J=8.3), 7.9-8.0 (1H, m), 8.01 (1H, bd, J=8.3), 8.20 (2H, d, J=8.3), 8.45 (1H, bd, J=7.9).
DMSO-d6
[0556] 2.2-2.3 (2H, m), 2.49 (2H, t, J=7.5), 3.39 (2H, t, J=7.5), 7.41 (2H, t, J=8.7), 7.78 (1H, bt, J=7.5), 7.92 (1H, bt, J=7.5), 8.01 (1H, bd, J=7.5), 8.32 (2H, dd, J=5.8, 8.7), 8.46 (1H, bd, J=7.5).
DMSO-d6
[0557] 2.2-2.3 (2H, m), 2.49 (2H, t, J=7.5), 3.38 (2H, t, J=7.5), 7.63 (2H, d, J=8.3), 7.77 (1H, bt, J=7.9), 7.91 (1H, bt, J=7.9), 8.00 (1H, bd, J=7.9), 8.26 (2H, d, J=8.3), 8.44 (1H, bd, J=7.9).
DMSO-d6
[0558] 0.91 (3H, t, J=7.1), 1.3-1.5 (4H, m), 1.9-2.0 (2H, m), 3.3-3.4 (2H, m), 6.94 (2H, d, J=8.7), 7.75 (1H, bt, J=7.9), 7.8-7.9 (1H, m), 7.99 (1H, bd, J=8.3), 8.11 (2H, d, J=8.7), 8.44 (1H, dd, J=0.8, 7.9).
EXPERIMENT EXAMPLE
[0559] Adenosine A3 Receptor Binding Capacity Test of Triazolopurine Derivative (1)
[0560] According to the method described in Molecular Pharmacology, 45, 978 (1994), an adenosine A3 receptor binding capacity test was performed.
[0561] A cell membrane of human renal endothelial cells HEK-293 transformed with plasmid coding an adenosine A3 receptor was isolated in a Tris-hydrochloric acid buffer (pH 7.7) in accordance with a conventional method, and then the cell membrane was treated with N6-(4-aminobenzyl)-9-[5-(methylcarbonyl)-β-D-ribofuranosyl]adenine (AB-MECA) labelled with 125I to prepare a cell membrane bound with the compound.
[0562] Then, this cell membrane and a test compound were incubated and the amount of [125] AB-MECA liberated was measured. The concentration of the test compound when 50% of [125I] AB-MECA is liberated, IC50, was determined from the measured value of the test compound at each concentration.
[0563] The adenosine A2 receptor binding capacity of the test compound were measured according to the method described in Archives of Pharmacology, 336, 204 (1987) and The Journal of Pharmacology and Experimental Therapeutics, 251 (3), 888 (1989) and then evaluated as IC50. The measurement results are shown in the following tables.
1TABLE 1
|
|
Receptor Binding Capacity (IC50) (nM)
Example No.Adenosine A2Adenosine A3
|
4189<10
5>10000<10
6>10000<10
7>1000019
8>10000<10
9>10000154
10>10000132
132723<10
22>10000255
23>1000028
26>1000026
27>10000<10
28>1000034
31>10000144
32531110
34>10000155
35>1000035
371445199
45>1000045
46>1000048
47>1000093
50>10000109
542495<10
552569<10
61>1000012
62>1000042
73>1000071
74>1000063
75>1000028
76>1000022
77>1000023
78>1000033
83>1000030
84>1000034
872859<10
93>1000037
113452612
1151563<10
133416024
152>1000032
|
Preparation Example 1
[0564] (Preparation of Tablets)
[0565] Two-thousands tablets, each of which contains 300 mg of the compound (5-n-butyl-2-phenylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine) obtained in Example 4 as an active ingredient, were prepared according to the following formulation.
2|
|
Compound obtained in Example 4600 g
Lactose (Japanese Pharmacopoeia) 67 g
Cornstarch (Japanese Pharmacopoeia) 33 g
Calcium carboxymethylcellulose 25 g
(Japanese Pharmacopoeia)
Methylcellulose (Japanese Pharmacopoeia) 12 g
Magnesium stearate (Japanese Pharmacopoeia) 3 g
|
[0566] According to the formulation described above, desired tablets were obtained by sufficiently mixing the compound obtained in Example 4, lactose, cornstarch and calcium carboxymethylcellulose, granulating the resulting mixture using an aqueous methylcellulose, passing the granules through a #24 mesh sieve, admixing the granules with magnesium stearate and compressing the admixture into tablets.
Preparation Example 2
[0567] (Preparation of capsules)
[0568] Two-thousands hard gelatin capsules, each of which contains 200 mg of the compound (5-n-butyl-2-(3,4,5-trimethoxyphenyl)-1,2,4-triazolo[1,5-c]quinazoline) obtained in Example 37 as an active ingredient, were prepared according to the following formulation.
3|
|
Compound obtained in Example 37400 g
Crystalline cellulose (Japanese Pharmacopoeia) 60 g
Cornstarch (Japanese Pharmacopoeia) 34 g
Talc (Japanese Pharmacopoeia) 4 g
Magnesium stearate (Japanese Pharmacopoeia) 2 g
|
[0569] According to the formulation described above, desired capsules were obtained by pulverizing the respective ingredients to form powders, mixing the powders to obtain an uniform mixture and filling a gelatin capsule for oral administration having a desired size with the mixture.
Preparation Example 3
[0570] (Preparation of Opthalmic Solutions)
[0571] Opthalmic solutions were prepared by dissolving 100 g of the compound obtained in Example 152, 10 g of benzalkonium chloride, 560 g of sodium bihydrogenphosphate and 800 g of potassium bihydrogenphosphate in water for injection to make 100 l and filling a container with the solution.
Claims
- 1. Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives represented by the general formula (1):
- 2. Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives according to claim 1, wherein the pyrazolotriazolopyrimidine derivative is represented by the following general formula (1-1):
- 3. Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives according to claim 1 or 2, wherein R2 is a phenyl group which optionally have one group selected from lower alkyl group, halogen atom, halogen-substituted lower alkyl group and hydroxy group as a substituent, or phenyl group which has 1 to 3 lower alkoxy groups.
- 4. Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives according to claim 3, wherein A is a pyrazole ring, or a benzene ring which is optionally substituted with one halogen atom as a substituent.
- 5. Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives according to claim 4, wherein R1 is an n-butyl group and R2 is a phenyl group which optionally has one group selected from lower alkoxy group, lower alkyl group, halogen atom and hydroxy group as a substituent.
- 6. Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives according to claim 5, which are selected from compound in which A is a pyrazole ring and R2 is a phenyl group having any one of lower alkoxy group, lower alkyl group or halogen atom as a substituent, compound in which A is a benzene ring and R2 is a phenyl group having one group selected from lower alkoxy group, halogen atom and hydroxy group as a substituent, and compound in which A is a benzene ring substituted with one halogen atom and R2 is a phenyl group.
- 7. Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives according to claim 6, which are selected from 5-n-butyl-2-(4-chlorophenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine, 5-n-butyl-2-(4-chlorophenyl)-1,2,4-triazolo[1,5-c]quinazoline, 5-n-butyl-2-(4-ethoxyphenyl)-1,2,4-triazolo[1,5-c]quinazoline and 5-n-butyl-9-chloro-2-phenyl-1,2,4-triazolo[1,5-c]quinazoline.
- 8. Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives according to claim 5, wherein R2 is a phenyl group which has a lower alkyl group or a halogen atom at the 4-position.
- 9. Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives according to claim 8, which are selected from 5-n-butyl-2-(4-chlorophenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine, 5-n-butyl-2-(4-fluorophenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine, 5-n-butyl-2-(4-methylphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine, 5-n-butyl-2-(4-chlorophenyl)-1,2,4-triazolo[1,5-c]quinazoline, 5-n-butyl-2-(4-bromophenyl)-1,2,4-triazolo[1,5-c]quinazoline and 5-n-butyl-2-(4-chlorophenyl)-9-chloro-1,2,4-triazolo[1,5-c]quinazoline.
- 10. Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives according to claim 9, which are selected from 5-n-butyl-2-(4-methylphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine and 5-n-butyl-24-bromophenyl)-1,2,4-tiazolo[1,5-c]quinazoline.
- 11. A pharmaceutical composition comprising a compound selected from the triazoloquinazoline and pyrazolotriazolopyrimidine derivatives of any one of claims 1 to 10, and a pharmaceutically acceptable carrier.
- 12. An adenosine A3 receptor affinitive agent comprising a compound selected from the triazoloquinazoline and pyrazolotriazolopyrimidine derivatives of any one of claims 1 to 10 as an active ingredient.
- 13. An intraocular-pressure reducing agent comprising a compound selected from the triazoloquinazoline and pyrazolotriazolopyrimidine derivatives of any one of claims 1 to 10 as an active ingredient.
- 14. A pharmaceutical preparation for prevention or treatment of glaucoma, comprising a compound selected from the triazoloquinazoline and pyrazolotriazolopyrimidine derivatives of any one of claims 1 to 10 as an active ingredient.
- 15. An intraocular-pressure reducing method, which comprises administering an effective amount of a compound selected from the triazoloquinazoline and pyrazolotriazolopyrimidine derivatives of claims 1 to 10 to a patient having an enhanced intraocular pressure.
- 16. Use of a compound selected from the triazoloquinazoline and pyrazolotriazolopyrimidine derivatives of claims 1 to 10 for reduction of an intraocular pressure of a patient having an enhanced intraocular pressure.
- 17. Use of a compound selected from the triazoloquinazoline and pyrazolotriazolopyrimidine derivatives of claims 1 to 10 for production of a preventive or remedy for glaucoma.
Priority Claims (1)
| Number |
Date |
Country |
Kind |
| 2001-28831 |
Feb 2001 |
JP |
|
PCT Information
| Filing Document |
Filing Date |
Country |
Kind |
| PCT/JP02/00874 |
2/1/2002 |
WO |
|
